Louisiana State University

LSU Digital Commons
LSU Doctoral Dissertations

Graduate School

2016

Chikungunya Virus Infection-Associated Bone and Joint Disease
Brad A. Goupil
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations
Part of the Veterinary Pathology and Pathobiology Commons

Recommended Citation
Goupil, Brad A., "Chikungunya Virus Infection-Associated Bone and Joint Disease" (2016). LSU Doctoral
Dissertations. 4273.
https://digitalcommons.lsu.edu/gradschool_dissertations/4273

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It
has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU
Digital Commons. For more information, please contactgradetd@lsu.edu.

CHIKUNGUNYA VIRUS INFECTION-ASSOCIATED
BONE AND JOINT DISEASE

A Dissertation
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy
in
The Department of Pathobiological Sciences

by
Brad A. Goupil
B.S., University of Connecticut, 2004
M.S., University of Connecticut, 2005
D.V.M., University of Minnesota, 2010
December 2016

ACKNOWLEDGEMENTS
I dedicate this dissertation to my wife, Dr. Margaret McNulty, who has supported and put up
with me for many years while I’ve been pursuing my seemingly never-ending education; and to my
daughter Olivia who can make me smile and laugh with the simplest expression or action, no matter
how stressful things get. Without their unending support and understanding, I wouldn’t have been
able to do this. I also have to acknowledge our furry children, past and present: Ronnie, Duncan,
Curious, Sherlock, Dax, Gopher, Annie, Mikie, Flash, Chester, and Gizmo, who have always provided
some much needed entertainment and recreation. I would like to thank my parents, Dr. Michael
Goupil and Ms. Pegi Goupil, who have always supported me through all the ups and downs without
fail, and have encouraged me to achieve any and all of my goals; my brother, Dr. Stephan Goupil,
whom I have always looked up to and has subsequently helped me strive to always be better and
achieve more; my sister, Mrs. Kristina Pinto, who has been a friend and confidant whenever needed,
without judgment; my nephew, Zachary Goupil, who helps me blow off a little steam and have some
fun during evening Xbox sessions; and my nieces, Nicole and Victoria Goupil, whom I don’t get to see
as often as I’d like, but put a smile on my face every time that I do.
I owe a great deal to my mentor, Dr. Christopher Mores, who has given me the freedom and
independence to pursue my interests in research, make my own mistakes, and find my own way,
while still providing guidance, support and insight whenever needed. To my unofficial mentor, Dr.
Rebecca Christofferson (v2.0), I will be forever grateful, as she has always been available for support
and guidance, and injected the necessary levity into my daily life when things got too stressful.
A special thanks to my mentors during my pathology residency at the University of Minnesota
as well, particularly Drs. Cathy Carlson and Erik Olson, whose unending enthusiasm for pathology
was infectious, and who showed me the fun and excitement of bones and joints, even if I fought it at
the time…
To my committee members, Drs. Juan Martinez, Ingeborg Langohr, Britton Grasperge, and my
Dean’s Representative, Dr. Cornelis de Hoop, thank you for the support, constructive criticism and
ii

advice. Your insights and suggestions have greatly helped improve my project and my time here at
LSU.
I would also like to thank my colleagues, former Mores Lab members, Dr. Michael McCracken
and Mr. Daniel Chisenhall, and current Christofferson Lab members, Ms. Anna Kawiecki and Ms.
Handly Mayton; your support and humor has been much needed and appreciated.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ...................................................................................................................... ii
LIST OF FIGURES .............................................................................................................................. vii
ABSTRACT ........................................................................................................................................... ix
CHAPTER 1: INTRODUCTION AND REVIEW OF CHIKUNGUNYA VIRUS-INDUCED
ARTHRALGIA: CLINICAL MANIFESTATIONS, THERAPEUTICS, AND PATHOGENESIS ................ 1
1.1 INTRODUCTION ................................................................................................................... 1
1.1.1 Background ............................................................................................................. 1
1.1.2 Disease Manifestations ........................................................................................... 2
1.1.3 Risk Factors for Disease Severity ........................................................................... 2
1.2 JOINT DISEASE ................................................................................................................... 4
1.2.1 Clinical Presentation................................................................................................ 4
1.2.1.a Symptoms.................................................................................................. 4
1.2.1.b Diagnosis ................................................................................................... 6
1.2.1.c Laboratory Results..................................................................................... 7
1.2.1.d Cytokines ................................................................................................... 8
1.2.1.e Advanced Imaging ..................................................................................... 9
1.2.1.f Histopathology/Pathology ......................................................................... 12
1.2.1.g Virus in Tissues ....................................................................................... 14
1.2.2 Treatment .............................................................................................................. 16
1.3 DISCUSSION ...................................................................................................................... 18
1.4 CONCLUSIONS .................................................................................................................. 22
CHAPTER 2: NOVEL LESIONS OF BONES AND JOINTS ASSOCIATED WITH CHIKUNGUNYA
VIRUS INFECTION IN TWO MOUSE MODELS OF DISEASE: NEW INSIGHTS INTO DISEASE
PATHOGENESIS ................................................................................................................................. 24
2.1 INTRODUCTION ................................................................................................................. 24
2.2 MATERIALS AND METHODS ............................................................................................ 26
2.2.1 Virus ...................................................................................................................... 26
2.2.2 Ethics Statement ................................................................................................... 27
2.2.3 Animal Models ....................................................................................................... 27
2.2.4 Microcomputed Tomography (µCT) ...................................................................... 28
2.2.5 Histopathology....................................................................................................... 29
2.3 RESULTS ............................................................................................................................ 30
2.3.1 C57BL/6 Mice ........................................................................................................ 30
2.3.2 IRF 3/7 -/- -/- Mice .................................................................................................... 33
2.3.3 Micro-computed Tomography (µCT) ..................................................................... 37
2.4 DISCUSSION ...................................................................................................................... 41
2.4.1 Cartilage – IRF 3/7 -/- -/- and C57BL/6 Mice ........................................................... 42
2.4.2 Periostitis and Periosteal New Bone – C57BL/6 Mice........................................... 42
2.4.3 Ischemic Necrosis of Bone Marrow – IRF 3/7 -/- -/- Mice ........................................ 43
2.4.4 Micro-computed Tomography (µCT) ..................................................................... 43
2.5 CONCLUSIONS .................................................................................................................. 45
CHAPTER 3: CHARACTERIZATION OF CHRONIC JOINT DISEASE ASSOCIATED WITH
CHIKUNGUNYA VIRUS INFECTION .................................................................................................. 47
iv

3.1 INTRODUCTION ................................................................................................................. 47
3.2 MATERIALS AND METHODS ............................................................................................ 49
3.2.1 Virus ...................................................................................................................... 49
3.2.2 Ethics Statement ................................................................................................... 49
3.2.3 Animal Models ....................................................................................................... 50
3.2.4 Serology ................................................................................................................ 50
3.2.5 Microcomputed Tomography (µCT) ...................................................................... 51
3.2.6 Histopathology....................................................................................................... 51
3.2.7 Immunohistochemistry .......................................................................................... 52
3.2.8 Statistics ................................................................................................................ 52
3.3 RESULTS ............................................................................................................................ 53
3.3.1 Histology ................................................................................................................ 53
3.3.2 Immunohistochemistry .......................................................................................... 54
3.3.3 Micro-computed Tomography (µCT) ..................................................................... 55
3.3.4 Serology ................................................................................................................ 56
3.4 DISCUSSION ...................................................................................................................... 56
CHAPTER 4: CHIKUNGUNYA VIRUS INFECTION ALTERS NEW BONE FORMATION
ASSOCIATED WITH PROGRESSION OF PRE-EXISTING OSTEOARTHRITIS ............................... 63
4.1 INTRODUCTION ................................................................................................................. 63
4.2 MATERIALS AND METHODS ............................................................................................ 65
4.2.1 Virus ...................................................................................................................... 65
4.2.2 Ethics Statement ................................................................................................... 65
4.2.3 Animal Models ....................................................................................................... 66
4.2.3.a Destabilization of the Medial Meniscus (DMM) Surgeries ....................... 66
4.2.3.b Viral Inoculations ..................................................................................... 66
4.2.4 Serology ................................................................................................................ 67
4.2.5 Microcomputed tomography (µCT)........................................................................ 68
4.2.6 Histopathology....................................................................................................... 68
4.2.7 Statistics ................................................................................................................ 69
4.3 RESULTS ............................................................................................................................ 70
4.3.1 Serology ................................................................................................................ 70
4.3.1.a RANKL ..................................................................................................... 70
4.3.1.b OPG ......................................................................................................... 70
4.3.1.c RANKL:OPG Ratio .................................................................................. 70
4.3.2 Histology/Histomorphometry ................................................................................. 70
4.3.2.a Synovium ................................................................................................. 70
4.3.2.b Articular Cartilage .................................................................................... 72
4.3.2.c Chondrocyte Cell Death........................................................................... 72
4.3.2.d ACS and Safranin O Stains ..................................................................... 73
4.3.2.e Subchondral Bone ................................................................................... 73
4.3.2.f Abaxial Osteophytes................................................................................. 73
4.3.3 Microcomputed Tomography (µCT) ...................................................................... 73
4.3.3.a Subchondral Bone ................................................................................... 73
4.3.3.b Medial + Cranial Osteophytes ................................................................. 75
4.4 DISCUSSION ...................................................................................................................... 77
4.4.1 Serology ................................................................................................................ 77
4.4.2 Synovitis ................................................................................................................ 79
4.4.3 Articular Cartilage .................................................................................................. 79
4.4.4 Osteophytes .......................................................................................................... 80
4.4.5 Subchondral Bone ................................................................................................. 80
v

4.4.6 Clinical Significance .............................................................................................. 81
CHAPTER 5: SUMMARY AND DISCUSSION .................................................................................... 85
REFERENCES .................................................................................................................................... 92
APPENDIX: CONSENT FORM .......................................................................................................... 109
VITA ................................................................................................................................................... 110

vi

LIST OF FIGURES
Figure 2.1. C57BL/6 mice sacrificed at 7 DPI......................................................................................30
Figure 2.2. Progression of lesions in C57BL/6J mice infected with chikungunya virus………………..31
Figure 2.3. C57BL/6 mice sacrificed at 21 DPI…………………………………………………………….32
Figure 2.4. Metatarsal bones of C57BL/6J mice at 21 DPI exhibiting periosteal bone proliferation
of woven bone………………………………………………………………………………………………….33
Figure 2.5. IRF 3/7 -/- -/- mice sacrificed at 5 DPI…………………………………………………………...34
Figure 2.6. Progression of lesions in IRF 3/7 -/- -/- mice infected with chikungunya virus [mice
were not evaluated on Day 3 post-infection]………………………………………………………………..34
Figure 2.7. Metatarsal bones and tarsal joints from IRF 3/7 -/- -/- mice…………………………………...36
Figure 2.8. Metatarsal bones from IRF 3/7 -/- -/- mice……………………………………………….......…37
Figure 2.9. Bone volume/total volume in CHIKV and control mice……………………………………....38
Figure 2.10. µCT scans of a CHIKV infected C57BL/6 mouse at 21 DPI…………………………….....39
Figure 2.11. Comparison of cortical bone parameters in normal control IRF 3/7 -/- -/- and C57BL/6
mice……………………………………………………………………………………………………………..40
Figure 3.1. Histopathologic lesions of bones and joints in CHIKV infected mice….………...………....54
Figure 3.2. Immunohistochemistry for CHIKV antigen on tissue sections............................................55
Figure 3.3. 2D slice from µCT scan of the mid-metatarsal region from a 30 DPI CHIKV infected
mouse demonstrating region of periosteal bone proliferation (arrowheads) on first metatarsal bone
(Mt1)…………………………………………………………………………………………………………….56
Figure 3.4. Serologic measurements of RANKL, OPG and RANKL:OPG ratio for mice at various
timepoints……………..………….......………..………….......………..………….......………..…..........….57
Figure 4.1. Serologic measurements of RANKL, OPG and RANKL:OPG ratio for mice at 4 and 8
weeks post-surgery/3 and 7 weeks post-inoculation………………………….…………………………...71
Figure 4.2. Histomorphometry results for articular cartilage measurements at 8 weeks
post-surgery/7 weeks post-inoculation, including articular cartilage area (AC.Ar) and thickness
(AC.Th), chondrocyte cell death area (CCD.Ar), and proportion of dead chondrocytes (CCD/AC)….72
Figure 4.3. Stifle joints from mice at 8 weeks post DMM surgery/7 weeks post inoculation..…...…....74
Figure 4.4. Histomorphometry results for subchondral bone and osteophyte measurements at 8
weeks post-surgery/7 weeks post-inoculation, including subchondral bone area (SCB.Ar) and
thickness (SCB.Th), and area of abaxial osteophytes (Ab.OP)……….......……………………………..75
vii

Figure 4.5. µCT results for subchondral bone and osteophyte measurements at 4 weeks post
surgery/3 weeks post inoculation and 8 weeks post surgery/7 weeks post inoculation, including
total medial + cranial osteophyte volume (Osteophyte TV), total subchondral bone volume (SCB
TV), and subchondral bone tissue density (SCB Tissue Density)……..………………………………...75
Figure 4.6. µCT 3D reconstructions of stifle joints from mice at 8 weeks post-surgery/7 weeks
post-inoculations…………..…………….........................………….……...………………………………..76

viii

ABSTRACT
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that circulates predominantly in
tropical and subtropical regions. Infection results in severe debilitating polyarthralgia during the acute
phase of disease, and reports suggest that chronic arthralgia lasting months to years after the initial
infection can occur. More severe and prolonged disease has been associated with pre-existing joint
disease, though this has not been experimentally examined. In the research presented herein, two
established mouse models (adult IRF 3/7 -/- -/- and wild-type C57BL/6J mice) were utilized to
characterize CHIKV-associated bone and joint disease and evaluate its impact on the progression of
pre-existing osteoarthritis (OA) utilizing histopathology, µCT, and serology. During acute stages of the
disease, CHIKV infection resulted in synovitis, cartilage necrosis, and periosteal necrosis or
periostitis. Additionally, IRF mice had severe ischemic bone marrow necrosis, and C57BL/6J mice
developed periosteal new bone proliferation. During chronic stages of disease (90 DPI), there was
ongoing and progressive synovitis, tendonitis, enthesitis, and cartilage damage, though periostitis and
periosteal bone proliferation had resolved. Infection with CHIKV in mice with pre-existing OA had no
significant impact on total synovitis scores or chondrocyte cell death, but caused a decrease in
volume of osteophytes and subchondral bone, as compared to OA alone. Serology results in both the
footpad and intra-articular C57BL/6J models indicated there were alterations in RANKL and OPG
associated with CHIKV infection, demonstrating potential changes in bone dynamics. The current
experiments demonstrated novel lesions of CHIKV-associated bone and joint disease that have
important ramifications for the treatment and prevention of disease. Periosteal bone proliferation
associated with CHIKV is a potentially painful but reversible process, whereas articular cartilage
damage is progressive and represents a potential mechanism for chronic CHIKV-associated joint
disease. Additionally, the alterations in bone associated with CHIKV infection and pre-existing OA, in
conjunction with changes in the RANKL-OPG pathways, could have significance in clinical monitoring
of OA and treatment choices in individuals with concurrent diseases. Future studies would help
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determine if RANKL and OPG levels could be useful for tracking disease progression in people and
establish the long-term effects of CHIKV infection on OA progression.
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CHAPTER 1: INTRODUCTION AND REVIEW OF CHIKUNGUNYA VIRUS-INDUCED
ARTHRALGIA: CLINICAL MANIFESTATIONS, THERAPEUTICS, AND
PATHOGENESIS
1.1 INTRODUCTION
1.1.1 Background
Chikungunya virus (CHIKV) is an arbovirus spread predominantly by Aedes aegypti and Ae.
albopictus mosquitoes99,159,184. It belongs to the Alphavirus genus along with other arthritogenic
viruses such as Ross River, Sindbis, O’nyong-nyong, Mayaro, Semliki forest, and Barmah forest
viruses50,99,111,178. There are 3 genotypes of CHIKV, named for the regions in which they generally
circulate: West African, East/Central/South African, and Southeast Asian23,99,125. CHIKV is considered
a neglected tropical disease, because it circulates within these subtropical and tropical regions, has
the potential to affect more than 1 billion people, and many at-risk people live in poverty stricken
regions182. Recently, CHIKV-induced disease was named a nationally notifiable condition in the
United States, because of a severe ongoing outbreak in the western hemisphere31. The outbreak
initially began in October of 2013 and has since spread throughout the western hemisphere, affecting
45 countries and territories and causing approximately 1.8 million reported suspected cases as of
March 2016124. In 2014, 2,811 cases of CHIKV-induced disease were reported in the United States,
which included 12 locally acquired cases in Florida29. While no locally acquired cases were reported
in the US in 2015, there is a significant risk of outbreak because of the ongoing epidemic in the
Americas and the widespread presence of competent mosquito vectors99.
Though there have been millions of people affected by CHIKV within the last decade, methods
of prevention and treatment are still lacking. Preventive measures focus on the mosquito vector and
include recommendations such as wearing long sleeves, making use of mosquito nets, elimination of
mosquito breeding sites and use of insecticides6. Several vaccines are in various stages of
development, though none are yet commercially available1,3,24,27,62,102,168. Treatments are non-specific
and predominantly focus on the alleviation of symptoms utilizing analgesics, antipyretics and non1

steroidal anti-inflammatory drugs (NSAIDS)93. Additional medications such as disease modifying antirheumatic drugs (DMARDs) utilized in cases of rheumatoid arthritis, and drugs that target specific
pathways of CHIKV pathogenesis are currently being investigated, but their efficacies are still
unknown53. Some of these specific drugs will be discussed in more detail later.
1.1.2 Disease Manifestations
Following infection with CHIKV, and an incubation period of 2-7 days, approximately 95% of
people will develop symptoms of disease6,153. The general symptoms consist of high fever,
headaches, rash, myalgia and severe joint pain, for which the virus was named: “chikungunya” is a
Makonde word in Tanzania meaning “to walk bent over” or “that which bends up”37. In most cases
these acute symptoms will resolve in approximately 2 weeks6. However, as many as 88% of people
can have arthralgia and/or arthritis persisting 1 month after the initial symptoms25, and in some
outbreaks, 50% of people reported chronic arthritis 1 year after the initial infection52.
Additionally, while less common, severe diseases affecting other body systems have been
reported. These can include gastrointestinal disease, neurologic complications including
meningoencephalitis and seizures, cardiovascular disease, hemorrhagic manifestations, and
death6,70,77,87,93. Reportedly, these severe disease manifestations are more frequent in children, the
elderly, and people that have underlying comorbidities41,93,116. Recently, maternal-fetal transmission
has also been reported, resulting in some neonatal mortality70,153. Research has indicated that these
neonatal infections occur in cases of mothers who are viremic at the time of parturition, and result
from perinatal exposure due to direct contact with maternal blood, rather than via placental transfer of
virus41,153. These neonatal cases occurred in approximately 3 out of 1,000 births during the La
Reunion outbreak93 and often resulted in severe manifestation in infants, including seizures,
hemorrhagic disease, and abnormalities in cardiac function87,153.
1.1.3 Risk Factors for Disease Severity
Numerous risk factors for development of severe disease in adult patients have been reported.
The patient’s age at the time of initial infection is one of the more consistently reported factors
2

associated with development of prolonged arthritis and other more severe disease manifestations6.
Disease is often considered to be more severe in adults than in children, though adults younger than
35 years appear to be protected151,160. In one report that had a particularly low prevalence of chronic
arthritis, the authors speculated that this may have been due to the high number of patients that were
less than 17 years old in that cohort160. Conversely, being 45 years old or older is considered to be a
risk factor for development of more severe disease56,160. However, it should be noted that some
studies have found no correlation between age and disease severity6. Similarly, while some studies
have reported an increased risk of severe disease in women6,39,133, others have demonstrated no
significant difference associated with gender13,151. Therefore, the role of age and sex in CHIKVassociated disease manifestations is still unclear.
An association between some of the more unusual disease manifestations described above
and presence of underlying comorbidities at the time of initial infection have been described in up to
71.6% of patients13. Some of the more commonly reported comorbities include hypertension and
respiratory or cardiovascular disease6,160. In regard to persistent joint disease in particular, ischemic
heart disease and diabetes have been implicated as risk factors13,151. Pre-existing joint disease has
also often been associated with an increased susceptibility to development of chronic CHIKVassociated arthritis77. Borgherini et al. reported that 44.3% of people who developed prolonged
arthritis had a history of chronic arthralgia, often as a result of osteoarthritis or gout13. Other studies
have similarly associated pre-existing arthritis, particularly osteoarthritis and rheumatoid arthritis, with
development of chronic CHIKV-associated arthralgia6,34,160. This has also been reported in other
arthritogenic alphaviruses such as Ross River virus and Sindbis-related (Pogosta) virus23. In fact, in
one multivariate model, the 3 variables that were independently associated with chronic CHIKVassociated joint disease were being 45 years old or older, the initial severity of joint pain, and
underlying osteoarthritis160. Although the association between existing joint disease and development
of chronic CHIKV-associated arthritis have been reported, it is unclear if persistent CHIKV-associated
disease is occurring, if CHIKV infection has a role in progression of existing joint disease, or if these
3

cases may just represent normal progression of pre-existing disease. However, in a cohort of patients
that developed chronic arthralgia following the La Reunion outbreak, only 2.8% had pre-existing joint
pain, indicating that there are likely other, as yet unidentified factors involved in the development of
this manifestation151. An additional confounding factor is that presence or absence of pre-existing joint
disease is often ascertained via self-reporting questionnaires, while thorough orthopedic evaluations
at the time of or prior to initial infection are rarely performed79,104,105,160,163. Therefore, association
between pre-existing joint disease and the risk of development of prolonged chronic CHIKVassociated disease is still unclear.
In addition to the existence of underlying joint disease at the time of infection, the severity of
the acute disease has also been linked to risk of development of persistent arthralgia and/or arthritis.
The parameters of initial disease severity that have been correlated with chronic disease include
presence of joint swelling, severity of joint pain, and a stronger Th1 immune response with concurrent
weak Th2 response during the acute phase of disease52,160,185. Other measures of initial disease
severity during acute disease were not associated with development of chronic disease, including the
initial viral load, number of joints affected, and duration of hospitalization151.
1.2 JOINT DISEASE
1.2.1 Clinical Presentation
1.2.1.a Symptoms
As mentioned, one of the most consistent and debilitating manifestations of CHIKV-induced
disease in people consists of an often widespread severe and incapacitating arthralgia and/or
arthritis, occurring in 85-100% of people with symptomatic infection70,91,151,160,181. In fact, this disease
manifestation is so common in CHIKV-induced disease, it has been reported that the presence of
concurrent high fever and arthralgia has a specificity of 99.6% and positive predictive value of 84.6%
for the diagnosis of CHIKV infection64. However, it should be noted that other arboviruses such as
dengue, Zika, and the other alphaviruses mentioned previously can all have similar clinical
presentations, including fever and arthralgia. Additionally, some of these, such as dengue, Zika, and
4

CHIKV are currently co-circulating in the western hemisphere144,175, thus care should be taken to
definitively identify the cause in any case with this presentation.
In most cases of CHIKV infection, patients develop symmetric oligo- or polyarthralgia15,
developing within minutes to days following the initial onset of fever6,15,53,143. While any joint can be
affected, those that are most commonly reported are the distal extremities such as wrists, metacarpal
and interphalangeal joints, as well as the ankles and metatarsophalangeal joints15,37,44,53,98,103,105,
though, some studies have indicated that the knee is also commonly affected6,36,39,105. Though the
majority of cases have this distribution of arthralgia, it is important to recognize that patient
presentation can vary and include asymmetric arthritis, monoarthralgia, and involvement of less
commonly affected joints, such as the elbow, hip, shoulder, and vertebral pain in sacroiliac,
lumbosacral, and cervical regions6,91,98. Arthralgia associated with CHIKV infection is often
considered to be the result of tenosynovitis and enthesopathy6,103,181 and can be associated with
paresthesia of the overlying skin77. Additionally, patients often complain of joint stiffness and have
variably apparent swelling of affected joints6,39,44,77. In many cases, these manifestations of arthralgia
will resolve within 1 to 4 weeks after the initial onset37,44,52,70.
However, in a wide range of cases (1.6-89.7%), patients can have chronic joint disease lasting
months to years after the initial disease onset, which can present as either an ongoing persistent
arthralgia, or relapsing arthralgia13,15,25,36,44,52,91,104,116,133,140,141,151,160,181,188. Some reports have
indicated that patients can have continued symptoms as long as 8 years after the initial infection181.
The distribution of joint manifestations in the chronic form is similar to the acute, including
symmetrical involvement of joints of the distal extremities, knee, shoulders, and rarely the
back13,37,104,160,181. In many instances, in a given individual, the same joints that were affected in the
acute phase are involved in the chronic phase44. Grossly apparent joint swelling is reported in 16.158.5% of chronic cases, and warmth and redness are usually not observed13,25,104. Again, these
symptoms are often associated with the presence of synovitis and/or tenosynovitis, and articular
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destruction has been rarely reported103,116. As many as 15% of patients develop Raynaud’s
syndrome, consisting of feelings of cold and numbness in response to cold and stress87,181.
While transient joint pain is not uncommon in the weeks to months following the resolution of
other disease manifestations such as fever and rash, the development of the chronic or relapsing
form of CHIKV-associated joint disease is poorly understood. Incidences of chronic CHIKVassociated joint disease have been fairly commonly reported since the La Reunion outbreak, though
it should be noted that in most reports, concurrent underlying joint abnormalities present prior to or at
the time of infection have not been ruled out104,116,151,160. Additionally, it is possible that some patients
develop joint disease such as osteoarthritis or rheumatoid arthritis, completely unrelated to the
previous CHIKV infection. Ambiguities in the pathogenesis of CHIKV-associated joint disease and the
potential continued or permanent damage that may occur during acute infection make proper
classification of chronic CHIKV-associated joint disease difficult. The potential mechanisms
associated with chronic CHIKV-associated joint disease are unknown, and no animal model currently
replicates this aspect of disease. Therefore, the association between CHIKV infection and chronic
joint pain is still unclear.
1.2.1.b Diagnosis
As discussed, the clinical presentation of CHIKV-associated arthralgia during the acute stages
can be quite similar to other arthritogenic alphaviruses and other tropical arboviruses such as dengue
and Zika144,175. Therefore, definitive diagnosis is required. Serological assays for detection of antiCHIKV IgM or IgG can be performed during the first few weeks or months, respectively, though false
negative results can occur depending on the stage of disease152. It should also be noted that false
positives have been reported as a result of cross-reactivity with other arboviruses27. However, this
cross-reactivity was likely more of a historical problem due to inferior assays and current serological
assays are considered to be able to distinguish CHIKV from flaviviruses and other alphaviruses, with
the exception of O’nyong nyong virus24. Various serological tests exist, including enzyme-linked
immunosorbent assay (ELISA), immunofluorescence, inhibition of haemagglutination, and
6

complement fixation27. Because of the high viremia associated with disease (see Laboratory Results
below), reverse-transcriptase polymerase chain reaction (RT-PCR) or virus isolation utilizing cell
culture or animal inoculation can be performed during the acute stage, but is only useful at 1 to 2
weeks post-infection during the viremia period24,27,152.
1.2.1.c Laboratory Results
In the acute stages of the disease, results of a complete blood cell count can be variable,
though leukopenia, often as a result of lymphopenia, is one of the most common presentations6,70,153.
This will often persist for the first week of infection, and is occasionally accompanied by
thrombocytopenia and an increased hematocrit6,153. In most instances, these parameters will return to
normal in the second week of infection70, though a persistent lymphopenia 36 months after the initial
infection has been rarely reported151. Alternatively, in some cases an increased CD4+ T cell count
has been described in chronic stages of disease103. Blood chemistry results are often normal
throughout the disease course, though increased liver enzymes including ALT and AST occasionally
occur6,70.
A high viremia is common in infected patients, frequently ranging from 108 to 1012 viral RNA
copies/mL, and lasting up to 12 days after the initial onset of clinical symptoms39,70,77,93. In many
cases, patients with higher viremias had more severe alterations in the above-mentioned CBC and
chemistry results39. Persistent viremias are not apparent during the chronic stage of disease103,151.
Infected patients will often seroconvert and have measurable IgG levels within the first week,
sometimes as early as 2 days post infection77, and lasting for years after the initial infection103.
Additionally, many studies have demonstrated persistent IgM levels in patients occasionally lasting 18
months or longer13,77,103,105,151. Neutralizing IgM antibodies can also be found in the synovial fluid of
patients 3 months after the initial infection116. An increased CHIKV IgG titer has been associated with
more severe and persistent joint disease22,56, though virus could not be detected in the blood or
synovial fluid22. Specifically, levels of IgG at 6 months post infection have been associated with
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increased symptom severity86. These findings suggest that continued immune stimulation could play
a role in some cases of prolonged CHIKV-associated arthritis.
In fact, several studies have suggested that chronic CHIKV-associated arthritis is similar to
rheumatoid arthritis (RA)6,15, in part due to similarities in clinical laboratory results. Many patients
even meet the requirements established by the American College of Rheumatology to be diagnosed
as having RA15,104. In one small study of 5 patients with chronic CHIKV-associated arthritis, all
patients were positive for rheumatoid factor (RF)181. In other studies, 13.6% to 57.1% of patients with
CHIKV-associated arthritis were RF positive15,37,181, though others reported no RF positivity in any
patients104. However, it should be noted that RF positivity is not a requirement for a diagnosis of RA.
Other similarities in laboratory results shared by CHIKV and RA include variably elevated
erythrocyte sedimentation rates, elevated C-reactive protein, and presence of anti-citrullinated protein
antibodies6,15,26,37,39,64,104. However, none of these are consistent findings in patients with acute or
chronic CHIKV-associated arthralgia. While in some cases patients with chronic CHIKV-associated
arthritis can be diagnosed as having RA6,105, many patients do not meet the criteria116. Thus the
association between CHIKV infection and development of autoimmune diseases such as RA remains
unclear23. In at least some of these cases, it is possible the development of RA is completely
unrelated to previous CHIKV infection. As current research has not determined a definitive link
between CHIKV infection and development of RA, a causal relationship should not be inferred at this
time.
1.2.1.d Cytokines
There has been abundant work performed analyzing cytokines in people infected with CHIKV
at various stages of disease. During acute stages (4-7 days post infection [DPI]), numerous cytokines
have been shown to be elevated including IFN-α, IL-1RA, IL-2, IL-4, IL-6, IL-7, IL-8, IL-12, IL-15,
MIG/CXCL-9, MIP-1α/CCL-3, HGF, bFGF, G-CSF, GM-CSF, and eotaxin/CCL-1139,52,180. Some
cytokines, such as IL-1β, IL-6, and RANTES have been correlated with disease severity39,127, though
increased levels of others are correlated specifically with higher viral load, such as IFN-α, IL-6, IL-16,
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IL-17, IL-1RA, MCP-1, IL-12, IP-10/CXCL-10, IL-18, IL-18bp39,52. At later timepoints in acute disease
(10-15 DPI), a shift towards Th2 cytokines such as IL-4 and eotaxin has been reported39, though
elevations in Th1 cytokines such as IL-12 have also been demonstrated52. Unfortunately most of
these studies do not specifically correlate cytokine profiles with joint manifestations, though Rulli et al.
reported that patients experiencing polyarthralgia had higher levels of MCP-1, TNF-α and IFN-γ147.
During later stages, various elevated cytokines have been associated with ongoing disease
and persistent arthralgia, such as IL-1RA, IL-17, IL-6, MCP-1, MIP-1α, MIP-1β, IL-8, GM-CSF, IFN-α,
and IL-1232,39,52,122,127,142. Increased levels of CXCL10 and CXCL9 have been associated with more
severe disease at 6 months post-infection86. While the majority of these studies focused on
serological analyses, cytokines such as IFN-α, IL-6, MCP-1, IL-8, and MMP2 have been
demonstrated within the synovium of a patient with chronic arthralgia, although not present in two fully
recovered patients52. Additionally, expression of IL-6 has been demonstrated in affected joints122.
Interestingly, it has also been report that patients who recovered from disease had higher levels of
HGF and eotaxin during the recovery period, than patients with continuing disease manifestations52
Unfortunately, many of the reports on cytokine profiles in patients report conflicting results52,122,180, so
the significances of these findings and their role in disease pathogenesis remains unclear. These
differences may reflect disparities in post-infection timepoints and/or differing techniques for analyzing
cytokine levels. Therefore their role or support in assessment of a clinical patient is also still unknown.
1.2.1.e Advanced Imaging
Much of the current literature focuses on the use of standard radiography for evaluation of
joints in CHIKV-infected patients6,15,77,103,104. While there is certainly some utility for this modality,
radiographs lack the sensitivity for more subtle changes that might occur early in the course of
disease, and are less useful for evaluating some of the associated soft tissues, as compared to other
imaging techniques such as magnetic resonance imaging (MRI) or ultrasonography.
The results of radiography are often variable in cases of CHIKV-associated disease. Some
significant bony changes, such as obvious bone erosions, can be seen by 10-18 months post
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infection (p.i.), involving the subchondral bone of the hands and wrists, including the interphalangeal
joints103,104; however, many patients have completely normal radiographs during this same time
period15. In some cases, patients who had normal radiographs at 10 months p.i. showed evidence of
joint space narrowing and bone erosions years after the initial infection15, indicating that radiography
may not be sensitive enough to be used in early evaluation of CHIKV-associated joint disease. In this
study, 42.9% of patients had normal radiographs at the time of diagnosis of chronic CHIKV arthritis,
while 57.1% had evidence of joint space narrowing and 23.8% had visible erosions15. However, at the
follow-up 24 months later, only 19% of patients had normal radiographs, and the percentages of
patients demonstrating joint space narrowing and erosions had both increased to 81%15.
Additionally, in some of these individuals with normal radiographs, MRI identified bone
erosions in the hands of 5 of 6 patients at the 24 month post-diagnosis timepoint15, indicating MRI
may be a more sensitive technique for early identification of joint disease. In fact, CHIKV-induced
arthritis has been compared to RA in regard to some of the pathologic changes, and studies have
indicated that radiographs of RA patients are often normal for 6-12 months after the initial symptoms
arise, though erosions can be demonstrated by MRI less than 6 months after symptom onset115.
MRI has also been shown to be able to identify significant bilateral periosteal inflammation,
carpal edema, and synovitis, which might not have been apparent on radiographs103. Other lesions
described on MRI of patients with CHIKV include joint effusion, synovitis/tendonitis/tenosynovitis,
bone marrow edema, and bone erosions affecting various regions including hands, wrists, knees, and
shoulders6,103,104. Additionally, while radiography has been shown to be useful predominantly at the
later timepoints as discussed above, in a report utilizing MRI, Mizuno et al. described bone erosions,
tenosynovitis, and joint effusions at 2 months p.i., indicating the utility of this modality at earlier
timepoints116. Simon et al. also demonstrated evidence of tenosynovitis by MRI involving multiple
tendons during the first month of disease manifestations, though boney erosions were not
described159. In one study, 80% of patients demonstrated significant lesions in CHIKV-associated
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chronic arthritis by 10 months post infection104 and in severe cases, tearing of menisci and cruciate
ligaments have also been described104.
Another benefit of MRI, as compared to other advanced imaging modalities, is that it can be
utilized to evaluate all soft and hard tissues, including tendons/ligaments, articular cartilage, and
bone, as well as for visualization of fluids, as in the case of joint effusion and soft tissue edema. In
fact, since the presence of fluid in and around joints is one of the earliest pathologic changes
associated with joint disease, the utility of MRI to identify acute changes associated with CHIKV
arthralgia is apparent. Because there are fewer restrictions on tissue types and pathologic changes
that can be evaluated by MRI, a wider spectrum of disease manifestations associated with CHIKV
infection can be assessed. For example, bone marrow edema was not a recognized component of
RA in people until MRI had been used to evaluate patients115. In fact, it has now been demonstrated
that sites of subsequent bone erosions are highly correlated with the locations of initially observed
bone marrow edema in patients suffering from RA115. This indicates a potential clinical utility in CHIKV
patients, in which it may be possible to identify locations at potentially higher risk for development of
subsequent bone erosions115. Similarly, synovitis adjacent to carpal bones was highly associated with
risk of development of erosions at that site115. Therefore, MRI scanning of CHIKV patients during the
acute phase of infection may be useful in predicting the outcome of disease at later timepoints.
Though the utility of MRI in clinical evaluations is clear, it should be noted that baseline MRI results
are not available for most CHIKV patients reported in the literature. Therefore, it is possible that some
lesions being associated with CHIKV infection may actually represent progression of disease already
present at the time of initial infection.
Ultrasonography has shown some utility for diagnosis of soft tissue disease associated with
CHIKV-induced arthralgia. Chopra et al. described substantial tenosynovitis and enthesopathy in
patients suffering from recurrent musculoskeletal discomfort in the months following CHIKV infection37
and Mathew et al. have similarly described tenosynovitis and bursitis105. However, due to the lack of
literature on ultrasonographic evaluation of patients with CHIKV, the consistency and reliability of this
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imaging technique for evaluation of manifestations of this disease is currently unknown. Additionally,
because ultrasound cannot image through bone due to the requirements of an acoustic window for
ultrasound visualization, deeper evaluation of joints including assessment of the articular cartilage
and some ligaments and tendons (e.g. cruciate ligaments) is not possible72. Another limitation of this
technique is that evaluation of the soft tissues associated with joints can be very challenging via
ultrasonography and requires a great deal of experience to obtain reliable and repeatable results. It is
likely that one would need to evaluate a large number of joints and in particular those of CHIKVinfected individuals before being able to make full use of this modality. Therefore, the utility of
ultrasonography in a clinical or research setting is unclear at this time.
1.2.1.f Histopathology/Pathology
Little histopathology has been performed on joint samples from CHIKV-infected human
patients. However, those that have been reported describe vascular proliferation, perivascular
macrophages, and synovial hyperplasia181. Macrophages also can extend into surrounding soft
tissues, including connective and peritendinous tissues and muscle35,52. In acute stages of disease,
CD4+ T helper cells are essential in the inflammatory process34, and intense activation of these cells
during this stage, in addition to dendritic cells (DC), natural killer cells (NK), and CD8+ T cells have
been associated with development of chronic arthralgia8. While synovitis is often assumed to be a
major component of disease in chronic CHIKV-associated arthritis, Jaffar-Bandjee et al. reported that
tenosynovitis, enthesopathy and periosteal inflammation are more common77. However, due to the
paucity of histopathological data associated with human disease, it is difficult to draw conclusions
regarding pathogenesis of disease manifestations.
The use of various animal models of CHIKV-associated joint disease has expanded the
knowledge regarding pathogenesis. Juvenile 3 to 4 week old C57BL/6 mice have demonstrated
synovitis, myositis and tendonitis peaking at around 7 DPI and generally completely resolving by 12
weeks p.i., with inflammatory cells consisting predominantly of macrophages and lymphocytes65. In
this study, the importance of CD4+ T cells in severity of acute disease was demonstrated by utilizing
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a Rag1-/- mouse lacking T and B cells, which developed more severe and prolonged inflammation
than a wild-type control65.
Models utilizing adult C57BL/6 mice have demonstrated development of mononuclear
synovitis, fibrinous exudate in joint spaces, and severe inflammation associated with skeletal muscle
adjacent to joints, with most of the inflammation resolving two weeks after infection55,129 and almost
complete resolution in all tissues by 30 DPI55. Immunohistochemistry/histochemistry in this model
demonstrated that there are large numbers of macrophages within these inflammatory infiltrates55,129,
and FACS confirmed the presence of monocytes/macrophages, NK cells, small numbers of B and T
cells, and dendritic cells, similar to what has been demonstrated in the previously described human
cases55.
Alterations in trabecular and cortical bone as evaluated by micro-computed tomography (µCT)
have also been demonstrated by 3 DPI utilizing a juvenile, 25-day-old C57BL/6 mouse model35.
These alterations were associated with an increase in TRAP+ cells within the bone marrow space,
potentially indicating a role for osteoclastic bone resorption in CHIKV-associated arthritis. However, it
should be noted that the authors also described a reduced growth plate width in this study. This, in
conjunction with the skeletal immaturity of this mouse model likely indicates that infection impacts
bone growth, development and modeling. This may indicate this model is more appropriate for what
may occur in neonates and children infected with CHIKV, rather than mechanisms associated with
disease in adults.
Nonhuman primate (NHP) models have been less successful for demonstration of arthritogenic
disease. The few existing published studies have variably reported no joint or muscle pathology70 or
fibrinous arthritis similar to that seen at early timepoints in mice at 7 DPI, only in animals receiving
high intravenous doses (107 pfu)93. These animals also often developed meningoencephalitis93.
However, NHPs receiving intermediate doses did not develop synovitis or meningoencepahlitis93,
thus the utility for use of NHPs in studying CHIKV-associated arthritis is currently unknown. However,
in-depth evaluation of joints has not been reported and NHP studies have confirmed the importance
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of macrophages in various other aspects of the disease, similar to that seen in humans and mouse
models52,93.
1.2.1.g Virus in Tissues
Again, data in regard to natural human infections, viral tropisms and persistence is limited,
though viral persistence in tissues is considered to be a potential mechanism of chronic disease. In
acute stages of disease, CHIKV antigen has been demonstrated within skeletal muscle progenitor
cells of infected patients and associated with muscle necrosis and inflammation8. Additionally,
persistent CHIKV infection in these muscle satellite cells has been demonstrated 3 months after the
resolution of the acute phase of disease105. During the acute phase, CHIKV can also be detected in
circulating monocytes68. Interestingly, persistent infection has also been demonstrated in synovial
macrophages as long as 18 months after the initial infection, demonstrating that viral persistence may
play a role in chronic disease34,35. Other articles have reported the presence of CHIKV antigen and/or
virus within fibroblasts of the joint capsule, skin, muscle fascia and dermis, though the timeline in
terms of infection in these is unclear41,93.
Again, numerous studies utilizing animal models have greatly added to our understanding of
CHIKV cell tropisms and viral persistence. Initially, viral replication occurs in the liver and then
disseminates to muscle, joints and dermis, similar to what has been shown in human biopsy
samples41. Between 3 and 5 DPI in wild-type C57BL/6 and IRF 3/7-/- mice, in situ hybridization (ISH)
has demonstrated the presence of CHIKV RNA in the cytoplasm of numerous cell types including,
skeletal myocytes, cells within the synovium and periosteum, endothelial cells, and cells
morphologically resembling fibroblasts and macrophages within the dermis145. Additionally, at 5 DPI,
virus has been demonstrated in the epidermis of IRF 3/7-/- mice145. In IFN α/β-/- mice, virus has been
demonstrated in fibroblasts within the synovium at 3 DPI, though infection of chondrocytes,
osteocytes and osteoblasts has not been demonstrated41. ISH in the IRF 3/7-/- mice showed
equivocal infection of chondrocytes145. Viral tropism for fibroblasts has been consistently
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demonstrated both in mouse models and in vitro and is believed to be one of the preferred cell types
for CHIKV41.
In cases of severe disease, virus has also been shown to disseminate to the CNS, specifically
the choroid plexus and leptomeninges, although parenchymal involvement has not been
demonstrated41. Various mouse strains including adult and neonatal C57BL/6, IFN α/β-/- and IRF 3/7-/mice have shown similar and consistent viral tropisms at early timepoints of disease41,145.
The presence and location of virus at later timepoints post inoculation (p.i.) is less clear. In
juvenile wild-type C57BL/6 mice, CHIKV RNA has been demonstrated in joint-associated tissues at
16 weeks p.i., while there was no presence of virus in any other tissues detectable after 14 DPI.65.
Interestingly, juvenile Rag1-/- mice demonstrated CHIKV RNA in joint associated tissues and muscles
at similar timepoints, suggesting that although T and B cells are able to clear virus from muscle, they
are ineffective at clearance from joint tissues65. These studies have utilized RT-PCR to demonstrate
viral presence, so exact localization of virus is unknown.
Nonhuman primate models have demonstrated similar results during acute stages of disease.
Reported viral tropisms included lymphoid tissues, liver, CNS, joint, and muscle, predominantly
infecting macrophages, dendritic cells and endothelial cells93. NHP models also showed a viral
tropism for the choroid plexus and leptomeninges, but spared the microvessels and parenchyma41.
Viral persistence at 19 DPI has been demonstrated by ISH in macrophages in the spleen, and
antigen persistence by IFA at 90 DPI within macrophages93. These studies involving NHP models
have suggested that macrophages act as the main cellular reservoir during chronic stages of infection
in various organs and tissues including the joints, muscle, lymphoid organs and the liver35,93.
Additionally, CHIKV RNA has been demonstrated within synovial tissues at 1.5 months p.i.93. All
studies involving animal models have shown a broad tropism for CHIKV, though fibroblasts and
macrophages in particular have been suggested as the preferred cell type and potential locations for
viral persistence.
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1.2.2 Treatment
Currently, specific treatment modalities for acute and chronic CHIKV-induced disease do not
exist, and the majority of treatment plans consist of supportive and symptomatic care. In acute stages
of the disease, this consists predominantly of rest, antipyretics and analgesics6. Unfortunately, solid
efficacy data for most treatment regimens are lacking87. Most regimens rely on non-steroidal antiinflammatory drugs (NSAIDs), whose efficacy can be quite variable, and resolution of acute arthralgia
can occur with or without their use64,116. Similarly, NSAIDs can have variable effects in chronic cases.
In one study in Bangladesh, 2 of 6 patients treated acutely with NSAIDs had persistent pain at 2-3
months64. In some cases joint pain may resolve, but stiffness remains178, perhaps suggesting
permanent alterations in articular or peri-articular tissues resulting in decreased mobility.
In cases refractory to NSAID treatment, short-term courses of corticosteroids have been
attempted with variable success. In some cases, steroids helped resolve symptoms of arthralgia,
tenosynovitis, entrapment syndromes and Raynaud’s syndrome181, while in other cases, these had no
effect53. In 1 case, there was initial improvement of symptoms, but synovitis persisted in the
metatarsal phalangeal joints26. Although corticosteroid treatments are usually not recommended due
to the potential for a severe rebound of arthritis and tenosynovitis after therapy is ended, in severe
cases of inflammatory polyarthritis refractory to NSAID treatment, the benefits may outweigh the
risks, and corticosteroid can be utilized158.
Because of the similarities between chronic CHIKV-associated arthralgia and RA, some
disease modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, leflunomide
and hydroxychloroquine have been utilized15. Again, the efficacies of these drugs are unclear53. In
some patients, 6 month treatments with methotrexate and hydroxychloroquine appeared to be of
benefit105, including clear improvement in severity of joint swelling, pain and tendon involvement
continuing for 15 months after initiation, as confirmed by MRI103. Other cases have demonstrated
almost complete resolution of symptoms in 4-6 months using methotrexate, sulfasalazine and
hydroxyochloroquine181. However, Bouquillard et al. reported that all patients in their cohort treated
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with DMARDs had demonstrated progression of disease evidenced by more severe radiographic
lesions at followup15.
A randomized trial on Reunion Island utilizing chloroquine demonstrated no difference in
duration of febrile arthralgia or severity of viremia153. Interestingly, in this study, patients receiving
chloroquine actually complained about their arthralgia more than the placebo group. Additionally, a
randomized trial in India comparing the efficacy of chloroquine compared to meloxicam demonstrated
no significant difference in pain reported in either group over the 24 week study period38. Although
patients in this study improved overall, the authors concluded that there was no advantage to use of
chloroquine as compared to NSAIDs or steroids. Additionally, there were elevated pro-inflammatory
cytokines (e.g. IL-6 and TNF-a) in patients that did not improve with treatment38. Another case
demonstrated no resolution of symptoms 16 months after initial infection, though no erosions had
developed by that timepoint26. Waymouth et al. reported that while chloroquine may be helpful in
more chronic stages, when given during the acute phase there was no benefit and patients were
more likely to report joint symptoms at 200 DPI181. Therefore, the efficacy and utility of chloroquine in
cases of CHIKV-induced disease remain unclear.
Neutralizing antibodies have also been tested as treatment modalities. If received prior to
infection, viremia and virus levels in ankles were decreased to below the level of detection in a mouse
model, however, when administered after infection, though viremia decreased, there were no effects
on the levels of viral RNA in the inoculated foot65. Whereas the utility of passive immunization using
monoclonal and polyclonal neutralizing antibodies in vitro and in mouse models have demonstrated
prophylactic protection from CHIKV infection, the utility in human patients either as a prophylaxis or
as a treatment during acute disease is unknown43,168. Similarly, although IFN-α treatment has been
shown to be able to prevent development of CHIKV-associated arthritis in a mouse model, this
efficacy only occurs when it is administered prior to infection48,168. Therefore, utility in a clinical setting
is unclear.
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The efficacies of specific antiviral medications are unknown, though ribavirin has shown some
potential. In vitro studies have demonstrated potential utility of ribavirin against alphaviruses24. In vivo,
in a small cohort of ten patients, decreased pain and swelling were reported in most patients135.
However, larger scale, controlled efficacy studies have not been performed to assess the true utility of
ribavirin in treating CHIKV-induced disease.
1.3 DISCUSSION
Extensive work focusing on the acute stages of CHIKV infection and utilizing animal models
has enhanced our current understanding of these early timepoints of disease. Although our
knowledge in this area has greatly increased in recent years, the role of CHIKV in development of
more chronic stages of disease has yet to be elucidated. As previously discussed, while numerous
reports describing chronic CHIKV-associated joint disease can be found in the literature, pre-existing
joint disease present at the time of initial infection have not been ruled out in these cases. Although
some reports utilized questionnaires to assess for presence of pre-existing joint disease, none
performed thorough orthopedic evaluations to definitively rule out existing joint disease79,104,105,160,163.
It is possible that subclinical joint disease existed in a subset of patients diagnosed with chronic
CHIKV disease and that infection had little to no impact on the subsequent progression. However, it is
also possible that CHIKV infection may exacerbate pre-existing subclinical joint disease and lead to
more rapid progression.
Additionally, even in the absence of identifiable pre-existing disease, it is possible that some of
the chronic CHIKV cases are a result of development of joint disease such as OA or RA, completely
unrelated to CHIKV infection. None of the current reports compare the incidence of OA or RA in a
subset of the population not infected with CHIKV. It is essential that thorough clinical workups of
patients during acute stages of disease be performed to evaluate for existing disease. Additionally,
more animal studies focusing on the effects of CHIKV infection on pre-existing disease would help
elucidate the relationships between these diseases.
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Viral persistence has also been suggested as a mechanism of chronic CHIKV disease. Some
animal models have demonstrated persistence as long as 16 weeks post-infection, often
accompanied by continued synovitis65. Even in humans, virus has been demonstrated within muscle
satellite cells 3 months after resolution of the acute phase of disease and in synovial tissues 18
months after initial infection24,105. Therefore, it is possible that this persistence could be responsible
for symptoms occurring within the weeks to months following initial infection.
Alternatively, induction of autoimmune disease following CHIKV infection has been put forth as
a possible mechanism of chronic joint disease23. This hypothesis has been mainly based on the fact
that some patients have been diagnosed with RA in the months to years following the initial
infection15,163. It is believed that infectious diseases can result in auto-immunity or exacerbation of
autoimmune diseases through mechanisms such as molecular mimicry, bystander activation, and
epitope spreading51. In fact, another alphavirus, Semliki Forest virus, has been linked to development
of an autoimmune demyelinating disease in a mouse model of experimental autoimmune
encephalomyelitis117. It has also been suggested that viral infection may play a role in the
pathogenesis of RA, as exposure to herpes-related Epstein-Barr virus and cytomegalovirus has been
associated with the development of RA6. Additionally, some microbial infections of the gastrointestinal
or urogenital systems have been associated with development of autoimmune reactions resulting in
reactive arthritis (ReA) and ankylosing spondylitis2,155,173.
However, the potential role of CHIKV and induction of autoimmunity is unknown. While
mechanisms for induction of autoimmune disease exist, it is possible that development of RA is
completely unrelated to previous CHIKV infection. More research is necessary, including prospective
analysis of acute and chronic clinical cases, to help determine the potential role of previous CHIKV
infection in chronic disease.
In particular, a more thorough focus on clinical workups of patients could add tremendously to
knowledge regarding CHIKV arthralgia and arthritis. A thorough evaluation for any pre-existing joint
disease at the time of initial presentation with CHIKV fever, coupled with multiple follow-up
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examinations at later timepoints of disease would greatly add to the understanding of CHIKV-induced
disease. Because of the variability in the clinical workups available in the literature, it is likely that
patients that are currently classified as having chronic CHIKV-associated arthritis actually represent a
heterogeneous group of conditions. In fact, a retrospective study examining patient outcome after the
Reunion Outbreak demonstrated that patients with chronic post-CHIKV joint disease could be variably
diagnosed with RA, spondyloarthropathies, undifferentiated polyarthritis or other musculoskeletal
disorders79.
Currently, the extent of the clinical evaluation performed on cases of chronic CHIKVassociated arthralgia/arthritis is highly variable, sometimes with only minimal diagnostics performed.
Results of laboratory tests including CBC, clinical chemistry, serology, synovial fluid analysis, and
advanced imaging diagnostics are highly variable and synovial biopsies for definitive characterization
and diagnosis are only very rarely performed41,71,103,105,116,151.
While more invasive methods such as synovial fluid samples and synovial biopsies could
undoubtedly add significant information to the growing body of knowledge on CHIKV pathogenesis,
these procedures are not without risk to the patients and therefore may require more substantial
justification. Additionally, these techniques can cause some level of discomfort and anxiety for
patients, thus obtaining volunteers for the initial procedures and ensuring their participation at
additional follow-up timepoints can be difficult. Because MRI is a non-invasive procedure and minimal
discomfort for the patient is expected, volunteer participation in clinical studies utilizing this modality
would likely be higher.
By utilizing advanced imaging techniques, particularly MRI, it would be possible to perform a
more thorough evaluation of potentially affected joints and associated soft tissues in CHIKV patients
with acute disease. Assessment of the extent of the acute lesions such as joint effusion, synovitis,
tendonitis, enthesopathy or bone marrow edema may make it possible to identify people with more
severe disease, potentially aiding in the choice of treatment strategies for those at greater risk for
developing chronic/relapsing disease. Additionally, the comparison of these early MRI analyses with
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later evaluations in patients who subsequently develop chronic or recurrent disease, may help to
further characterize disease pathogenesis.
While the data in the current literature in regard to MRI analyses of CHIKV patients with
chronic disease is interesting and informative, the lack of baseline scans on these individuals makes
the interpretation of results more challenging. In some cases, it might not be possible to differentiate
between pathologic changes that are direct results of previous CHIKV infection and subsequent
disease, and those that are associated with other, potentially unrelated comorbidities present at the
time of initial infection, such as OA or RA. By performing baseline scans at early timepoints in
infected patients, not only can the acute manifestations of disease be better characterized, but the
presence of any pre-existing disease can be determined, and the progression of CHIKV disease can
be further evaluated by comparing the initial scans to follow-up scans in patients with chronic disease.
Furthermore, by obtaining these evaluations of CHIKV patients, and pairing them with current
ongoing research using animal models, a more thorough understanding of the pathogenesis of
CHIKV-induced arthralgia and/or arthritis can be elucidated, and thus novel methods of treatment and
prevention may be discovered.
However, the value of the more traditional and invasive methods of sampling including synovial
fluid collection and synovial biopsy should still be recognized. Because the acute presentation of
CHIKV-associated disease as visualized by MRI is currently unknown, it is possible that scans
performed at early timepoints will provide only minimal information in regard to disease status, or that
the acute presentation will be variable among patients and therefore the interpretation of results might
be challenging. Therefore, the pairing of MRI scan results and synovial fluid samples or biopsies
obtained during the acute phase would be ideal. Should this prove to be too difficult or impossible for
clinical studies, these early scans may still provide valuable information, and can certainly be
extremely useful when paired with follow-up scans during the chronic phase. By including a minimum
database of clinical information such as patient gender and age, basic clinical parameters, and
evaluation of absence or presence and extent of clinical symptoms such as arthralgia, joint stiffness,
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and myalgia, the utility of MRI results can be maximized, even in the absence of data associated with
more invasive procedures.
These initial assessments might also be useful for guiding treatment options in patients. In
many instances of less severe manifestations of joint disease associated with CHIKV infection,
symptomatic treatment with antipyretics, NSAIDs, analgesics, and/or corticosteroids have been
shown to be effective in alleviating symptoms116,178,181. However, in some more severe cases, the
arthralgia and/or arthritis has proven to be resistant to these treatments, and additional more specific
therapies, such as antivirals (e.g. acyclovir, ribavirin), cytokine-directed therapies (e.g. anti-IL-6
antibodies, TNF antagonists), and disease modifying anti-rheumatic drugs (DMARDs) have been
attempted, with variable results15,26,38,53,64,87,103,105. Visualization of more severe joint manifestations of
disease via MRI may help identify patients that would benefit from more aggressive therapies and/or
be candidates for more frequent clinical follow-up evaluations.
As previously mentioned, treatment of CHIKV arthralgia and/or arthritis is difficult and no
proven regimens currently exist. Generally, non-specific treatments such as NSAIDs and analgesics
are utilized, with varying success. Additionally, immunosuppressive therapies that are utilized for RA
have variable efficacies. Because of the ambiguities in mechanisms associated with both acute and
chronic stages of CHIKV associated arthralgia, it is difficult to determine an appropriate treatment
plan. Even in arthritides that have been better studied, such as OA and RA, treatment regimens may
not offer substantial improvement in clinical signs or significantly slow the progression of disease.
Even if similar mechanisms are at work in acute and chronic stages of CHIKV, treatments will likely
still be variably successful. Additional research is required focusing on these pathogenic mechanisms
and testing treatment modalities to clear up some of these ambiguities.
1.4 CONCLUSIONS
Though it has become commonplace to state that CHIKV can result in chronic arthralgia and/or
arthritis, the evidence for this is lacking and potential pathogeneses are unknown. It seems clear that
joint pain could persist for weeks to a couple of months in some cases, but care should be taken to
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assume that there is a connection between initial CHIKV infection and chronic joint pain lasting
months to years. Currently, in all available reports, pre-existing joint disease, or development of an
unrelated joint disease such as OA or RA cannot be ruled out. The use of advanced imaging
techniques, in conjunction with currently accepted methods of detection and evaluation of CHIKVinfected patients, could fill a significant gap in regard to early identification of patients at risk for
developing ongoing joint disease associated with infection, and the characterization of the
pathogenesis of arthralgia/arthritis.
There is currently no definitive evidence that treatments beyond conservative NSAID therapy
in more severe cases have any efficacy. It should also be noted that aspirin is not recommended due
to bleeding risk168. In cases refractory to pain alleviation by NSAIDS, weak opioids such as tramadol
or codeine can be added158. Although investigations into alternative treatments such as inhibitors of
viral replication, anti-cytokine therapies, and siRNA have occurred, their efficacies and utilities in a
clinical setting are still unknown32,168.
While animal models have been useful to study acute joint disease demonstrating evidence for
viral persistence, no model exists for development of chronic joint disease associated with CHIKV
infection. Therefore, to further elucidate the potential role of CHIKV in chronic cases and to establish
the efficacy of alternative therapies, clinical studies are required. There is a great need for reporting
clinical information associated with both acute and chronic cases.
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CHAPTER 2: NOVEL LESIONS OF BONES AND JOINTS ASSOCIATED WITH
CHIKUNGUNYA VIRUS INFECTION IN TWO MOUSE MODELS OF DISEASE: NEW
INSIGHTS INTO DISEASE PATHOGENESIS1
2.1 INTRODUCTION
Chikungunya virus (CHIKV) is an alphavirus in the Togaviridae family. The word ‘chikungunya’
is roughly translated to “that which bends up” or “to walk bent over” from the Makonde language in
Tanzania and is so named because of the severe incapacitating arthralgia that occurs with
infection6,116. CHIKV is an enveloped, positive sense RNA arbovirus spread predominantly by Aedes
aegypti and Ae. albopictus mosquitoes39,41,127.
Historically, the geographical distribution of CHIKV has been restricted to tropical and
subtropical regions throughout Africa and Asia, particularly the Indian subcontinent. There are three
currently recognized genotypes of virus endemic in these areas, defined as the Eastern/Central/South
African, West African, and Asian genotypes177. Due to the expanding range of the vector Ae.
albopictus and the continually increasing ease of international travel and commerce, CHIKV has
recently extended into temperate regions9,27,63,116,170. Most recently, beginning in October of 2013, the
virus has emerged and rapidly spread throughout the Caribbean and the Americas, resulting in more
than 1.6 million suspected cases and 270 deaths as of October 15, 2015123. It has been determined
that the strain circulating in this region belongs to the Asian genotype53.
Approximately 95% of people that are infected with CHIKV will become symptomatic, which
consists predominantly of high fever, rash, and debilitating arthralgia6,15,37,181. While in the majority of
cases symptoms resolve approximately two weeks after onset, some patients can develop ongoing
symptoms of arthralgia lasting months to years after the initial infection13,25,52,116,141,143,160,181. Most
commonly, there is symmetrical involvement of distal joints including those of the ankles, wrists, and
digits, though any joint can be affected6,37,104,160. Although there are numerous reports of clinical
1

This chapter previously appeared as Goupil, B. A. et al. Novel Lesions of Bones and Joints
Associated with Chikungunya Virus Infection in Two Mouse Models of Disease: New Insights into
Disease Pathogenesis. PloS one 11, e0155243, doi:10.1371/journal.pone.0155243 (2016). It is
reprinted by permission of “PLOS Publications”
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workups on patients suffering from chronic CHIKV-associated arthralgia, the mechanisms involved in
the development of disease and their association with initial viral infection are
unclear6,53,79,103,104,158,160,181. However, some reports suggests that chronic CHIKV-associated arthritis
is an erosive and inflammatory arthritis with similarities to rheumatoid arthritis104,120. Diagnostic
imaging techniques such as radiography and MRI have demonstrated evidence of loss of articular
cartilage and bony erosions in affected joints of patients with histories of CHIKV infection15,104,116,158.
However, it should be noted that in these cases, these chronic joint manifestations cannot be
unequivocally attributed to previous infection with CHIKV, as other concurrent joint diseases such as
rheumatoid arthritis or osteoarthritis cannot be ruled out.
The arthralgia and/or arthritis associated with CHIKV infection represents a significant
component of the clinical picture of both acute and chronic disease, though there are still gaps in
knowledge regarding the pathogenesis of these manifestations. Current hypotheses for chronic
disease include viral or antigen persistence within tissues of the joint (e.g. synovium) resulting in
ongoing direct damage from viral infection, replication and/or immune-mediated tissue destruction, or
induction of a post-infection autoimmune condition8,39,51,67,103. The challenge in elucidating these
mechanisms of bone and joint disease is that animal models of chronic CHIKV-associated arthralgia
and/or arthritis are lacking, and existing models of acute disease do not necessarily replicate all
aspects of human disease manifestations41,93,167. While existing models can recapitulate some
aspects of disease, involvement of the articular cartilage and bone in particular have rarely been
definitively demonstrated69,129. In addition to the bone and joint manifestations of disease, in rare
cases, CHIKV infection can result in more severe disease manifestations, including
mortalities41,70,77,87,137.
There are currently several existing animal models including mice and non-human primates
that are considered appropriate for evaluation of CHIKV-associated disease as experimental
models42,70,167. Two models that most closely replicate consistent joint involvement associated with
CHIKV infection include the IRF 3/7 -/- -/- mice, which have a deficient type 1 interferon response, and
25

adult, wild-type C57BL/6 mice55,145,150. The IRF 3/7 -/- -/- mice develop a fatal form of disease, similar to
that seen in some of the more severe manifestations of disease in people145,150, though the C57BL/6
mice develop a more protracted form of disease, similar to that seen in the majority of human cases55.
Both models have been shown to develop significant viremia following viral inoculation in the dorsal
or ventral surface of the hind foot, exhibit evidence of some myositis, synovitis, and tendonitis
associated with infection, and CHIKV has been demonstrated locally within the tissues of the
foot55,145,150. While these two mouse models develop consistent CHIKV-associated disease, some of
the manifestations of joint disease seen in humans, including damage to the articular cartilage,
alterations of bone including bony lysis, have rarely, if ever been described. Additionally, none of
these models have demonstrated utility for use in chronic CHIKV-associated disease studies.
By utilizing these two established animal models of disease, this study aimed to 1)
demonstrate, describe and evaluate pathologic findings in both articular cartilage and bone
associated with CHIKV infection, 2) examine these aspects of disease manifestations over time at
various points throughout the disease course, and 3) evaluate these models for potential use in
chronic studies of CHIKV-associated arthralgia/arthritis. We suspect that a thorough evaluation of
bone and joint pathology associated with CHIKV infection will reveal previously unrecognized lesions
in these existing mouse models. We hypothesize that CHIKV infection will result in degeneration of
articular cartilage and osteoclastic bone resorption associated with synovitis.
2.2 MATERIALS AND METHODS
2.2.1 Virus
A Southeast Asian strain of CHIKV (SVO 476-96) was utilized for this project and was a
generous gift from the World Reference Center for Emerging Viruses and Arboviruses at the
University of Texas Medical Branch. The isolate was originally obtained from a human sample in
Northeast Thailand in 1996 and was passaged twice in LLC-MK2 cells and once in Vero cells prior to
being obtained by our laboratory. The virus was passaged one additional time in Vero cells prior to
utilization in this project.
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2.2.2 Ethics Statement
Housing of animals utilized in this study and the methods employed during animal
experimental procedures were reviewed and approved by the Louisiana State University (LSU)
Institutional Animal Care and Use Committee (IACUC) which complies with the guidelines stated in
the National Institutes of Health’s (NIH) Guide for the Care and Use of Laboratory Animals. These
experiments were conducted under the approved LSU IACUC protocol #15-005 (approved in 2015).
2.2.3 Animal Models
Two established mouse models of CHIKV infection were utilized: IRF 3/7 -/- -/- mice on a
C57BL/6 background (≥ 8 weeks of age; males and females) and C57BL/6J mice (≥ 8 weeks of age;
females only). C57BL/6J mice were obtained from a distributor (The Jackson Laboratory,
https://www.jax.org/). The IRF 3/7 -/- -/- mice were originally obtained as a generous gift from Dr.
Michael Diamond (Washington University, St. Louis, MO) with permission from Dr. T. Taniguchi
(University of Tokyo, Tokyo, Japan). A breeding colony was subsequently established and maintained
in the BSL3 laboratory at the Louisiana State University (LSU) School of Veterinary Medicine (SVM).
Mice were housed in groups of 4 or 5 in micro-isolator cages in the BSL3 laboratory of the LSU
SVM. Mice were provided water and a standard commercial mouse food (LabDiet, Land O’ Lakes,
Inc., St. Louis, MO) ad libitum throughout the experiments. Prior to infection, mice were initially
anesthetized with isoflurane followed by intraperitoneal injection of a ketamine (40 mg/kg) and
xylazine (2 mg/kg) solution. Subsequently, mice were intradermally (IRF 3/7 -/- -/- mice) or
subcutaneously (C57BL/6J mice) injected in the caudoventral aspect of the hind foot near the tarsal
joint with 2x104 PFU of virus. As negative controls, age and sex-matched mice were injected with a
similar volume (10µl) of sterile PBS. Mice were then euthanized at various timepoints throughout the
disease course (1, 2, 4, 5, 6, 7 days post infection [DPI] for the IRF 3/7 -/- -/- mice and 7, 14, 21 DPI for
the C57BL/6J mice). During experiments, animals were monitored a minimum of once (C57BL/6J
mice) or twice (IRF-3/7-/- -/- mice) daily for clinical signs associated with illness, including lethargy,
abnormal posture, joint swelling, lameness, limb gnawing, and loss of body weight. If at any point
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during the experiments, mice were determined to be in significant distress or exhibited a loss of 20%
or greater of initial body weight, they were immediately euthanized to reduce pain and suffering. At 5
DPI, 4 of the IRF 3/7 -/- -/- mice were moderately lethargic and were subsequently euthanized at that
time. Due to the rapid progression of the fatal disease that occurs in the IRF 3/7 -/- -/- mice, 6 mice died
during the experiment, though, with the exception of foot swelling, no additional clinical signs were
observed in these mice prior to their death (4 mice at 5 DPI, 1 mouse at 6 DPI, and 1 mouse at 7
DPI). Mice were euthanized via CO2 asphyxiation followed by cervical dislocation. All experiments
were performed in accordance with LSU IACUC guidelines (protocol #15-005).
2.2.4 Microcomputed Tomography (µCT)
Intact hindlimbs were collected from mice and scanned using µCT. Two regions of interest
(ROI) scanned for each mouse included: 1) the stifle joint extending from approximately mid-shaft of
the femur to mid-shaft of the tibia and fibula, and 2) the distal hindlimb extending from the proximal
aspect of the tuber calcanei to the distal phalanges. Specimens were placed in holders for scanning
by µCT (Scanco model 40; Scanco Medical AG, Basserdorf, Switzerland). Samples were scanned in
a transverse plane in 70% ETOH at 55kV, 0.3-second integration time, with a 16 µm voxel size in
plane and a 16 µm slice thickness. To evaluate differences in bone morphology within age-matched
IRF 3/7 -/- -/- mice (n=11) compared to wild-type C57BL/6J controls (n=9), the humeri were dissected
free from surrounding soft tissue and scanned in 70% ETOH at 55kV, 0.3-second integration time,
with a 10 µm voxel size in plane and a 10 µm slice thickness.
To evaluate trabecular bone morphology secondary to CHIKV infection within the stifle joint
region, two ROIs were evaluated: 1) the proximal epiphysis of the tibia extending from the
subchondral bone to the proximal physis as has been previously evaluated35, and 2) the distal
metaphysis of the femur, extending from approximately mid-shaft to the distal physis, which is
considered the appropriate location to evaluate trabecular bone morphology16. The proximal 30% of
the humerus, extending distally from the proximal physis, was the ROI used to evaluate changes in
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trabecular morphology within the IRF 3/7 -/- -/- strain compared to wild-type C57BL/6J controls, and a
region at midshaft was used to evaluate cortical bone.
The proper thresholds for 3D reconstructions to qualitatively evaluate overall bone
morphology, in addition to appropriate thresholds to quantitatively evaluate trabecular bone, were
tested and the same thresholds were used throughout the study for all ROIs. For trabecular bone,
bone volume (BV), total volume (TV), BV/TV, tissue density, apparent density, trabecular number
(Tb.N), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), connectivity density (Conn.D),
structural model index (SMI), bone surface (BS), and degree of anisotropy (DA) were evaluated. For
cortical bone, cortical area (Ct.Ar), thickness (Ct.Th), and porosity (Ct.Po), total cross-sectional area
(Tt.Ar), and Ct.Ar/Tt.Ar were evaluated. Established procedures and nomenclature were used for all
variables16.
2.2.5 Histopathology
Immediately following euthanasia, entire mice were fixed in 10% neutral buffered formalin for a
minimum of 48 hours. Following fixation and after evaluation via µCT, the entire hind feet of mice
(ipsilateral and contralateral) were sagittally bisected and decalcified in 10% EDTA for 21-28 days.
Samples were then routinely processed for histopathologic evaluation. Briefly, samples were
dehydrated in increasing concentrations of ethanol and embedded in paraffin wax. Subsequently, 4-5
µm thick sections were adhered to positively charged glass slides. Sections were routinely stained
with hematoxylin and eosin (H&E) for evaluation. Standard Masson’s trichrome stains were
performed on select slides. All histologic evaluations were performed by a board-certified veterinary
anatomic pathologist (BAG). All slides were evaluated using a Nikon Eclipse Ni-U upright microscope
(Nikon Instruments Inc., Melville, New York) and digital images were obtained using an attached
Olympus DP72 microscope digital camera (Olympus Corporation, Tokyo, Japan).
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2.3 RESULTS
2.3.1 C57BL/6 Mice
At 7 DPI, all virally infected mice exhibited moderate to marked swelling of the inoculated feet
(Figure 2.1). This swelling had resolved by 14 DPI in all mice. These findings are similar to those
previously reported in this mouse model55.

Figure 2.1. C57BL/6 mice sacrificed at 7 DPI. (A) CHIKV inoculated mouse demonstrating significant
swelling of the inoculated foot (right foot; red box). (B) PBS sham inoculated mouse demonstrating no
swelling associated with inoculation (right foot).
Initial histopathologic evaluation of some aspects of CHIKV infection in the feet of adult
C57Bl/6 mice has been previously reported55. Similar findings were observed in the current
experiment, including moderate mononuclear inflammation in the deep dermis and subcutis,
extensive myocyte necrosis and inflammation, tendonitis, and synovitis. A more detailed histologic
evaluation in the current experiment demonstrated additional novel lesions associated with CHIKV
infection. An overview of the various lesions and their time courses are presented in Figure 2.2.
In 100% of mice, the predominant change in the skeletal muscle consisted of acute myofiber
degeneration and necrosis accompanied by minimal cellular infiltrates consisting predominantly of
macrophages and fewer neutrophils. Joint lesions primarily affected the tarsal joints in 100% of mice,
and consisted of loss of the lining synoviocytes of the intima and infiltration of the subintima by small
numbers of mononuclear cells and neutrophils. There were rare regions of equivocal cartilage
necrosis in few mice, though no definitive foci were apparent. Affecting the metatarsal bones of 3 of 4
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infected mice (75%), there were occasional areas of minimal to mild expansion and hypercellularity of
the periosteum (periostitis). Rarely, within the tibia and metatarsal bones of 1 mouse (25%), there
were small areas of bone marrow edema characterized by accumulation of variably sized pools of
pale eosinophilic, homogenous material.

Figure 2.2. Progression of lesions in C57BL/6J mice infected with chikungunya virus.
At 14 DPI, the necrosis and inflammatory component within the skeletal muscle was similar to
that observed at 7 DPI, however, there was also evidence of myofiber regeneration characterized by
the presence of large myocytes containing basophilic cytoplasm and internalized nuclei exhibiting
nuclear rowing. More distal joints including the tarsometatarsal, metatarsophalangeal and
interphalangeal joints were also similarly affected in all mice. Similarly to 7 DPI, there were rare
regions of equivocal cartilage necrosis in few mice, though no definitive foci were apparent. Four of 4
mice (100%) had consistent mild periostitis affecting the majority of the length of the metatarsal
bones. Areas exhibiting more significant periostitis were often immediately adjacent to more extensive
regions of necrosis and inflammation within the skeletal muscle. Bone marrow edema was not
observed in any mice at this timepoint.
At 21 DPI, in the skeletal muscle, the necrosis was beginning to resolve and regeneration was
more prominent and accompanied by some loose fibrous connective tissue replacing areas of
myofiber dropout (Figure 2.3, A). The subintimal mononuclear infiltrates within the synovium had
increased and consisted predominantly of lymphocytes and plasma cells, consistent with a subacute
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lymphoplasmacytic synovitis affecting 4 of 4 mice (100%). Synoviocytes, when present, were often
hypertrophic and trichrome stains demonstrated increased fibrous connective tissue within the
synovium (Figure 2.3, C). Two of 4 mice (50%), had foci of necrotic articular cartilage.

Figure 2.3. C57BL/6 mice sacrificed at 21 DPI. (A) Skeletal muscle exhibiting multifocal areas of
ongoing necrosis (arrows) and extensive myofiber regeneration (arrowheads). (B) Skeletal muscle
from a similar location of a normal PBS-inoculated control mouse. (C) Tibiotarsal joint demonstrating
deposition of fibrous connective tissue within the synovium (arrows) (Masson’s trichrome stain). (D)
Tibiotarsal from a PBS-inoculated control mouse demonstrating normal synovium (Masson’s
trichrome stain). (S = synovium, B = bone)
Affecting 4 of 4 (100%) virally infected mice, there was extensive, moderate periostitis. In 2 of
4 (50%) of these mice, on the plantar surface of the diaphysis of the metatarsal bone, within areas of
periostitis, there were focal regions of mild proliferation of immature woven bone beneath the
periosteum (subperiosteal bone proliferation) (Figure 2.4, A). These foci were limited to this location
and not seen in other bones of the foot. Within these areas, lining the periosteal new bone, there
were numerous elliptical cells with basophilic cytoplasm, a perinuclear clear zone and
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heterochromatic nuclei (consistent with activated osteoblasts). Occasionally, within the periosteum
and associated with either periosteal new bone or the periosteal surface of adjacent cortical bone,
there were few large, polygonal to round, multinucleated cells occasionally found within scalloped
margins of bone (Howship’s lacunae), consistent with osteoclasts actively resorbing bone (Figure 2.4,
B). Bone marrow edema was apparent in 75% of mice.

Figure 2.4. Metatarsal bones of C57BL/6J mice at 21 DPI exhibiting periosteal bone proliferation of
woven bone. (A) Periosteal bone proliferation (arrowheads) and few large multinucleated cells within
scalloped lacunae (osteoclasts, arrows) along the superficial margin of the periosteal new bone, just
deep to the periosteal lining. (B) Periosteal bone proliferation (arrowhead) and osteoclasts (arrows)
are apparent along the cortical surface of the bone. (C) Metatarsal bone from a PBS-inoculated
control mouse demonstrating normal periosteum (arrowhead).
2.3.2 IRF 3/7 -/- -/- Mice
Similarly to what has been previously reported in this mouse model145,150, grossly apparent
swelling of the virus-inoculated feet was apparent by 2 DPI and reached its maximum at 4 DPI. While
measureable swelling of the contralateral feet did not occur, mild hyperemia was apparent when
compared to the PBS control mice (Figure 2.5). No additional significant gross findings were
apparent.
Initial histopathologic evaluations of IRF 3/7 -/- -/- mice infected with CHIKV have been reported
previously145,150 and lesions similar to those described were also observed in the current experiment.
These included multifocal epidermal necrosis, dermal edema, inflammation and hemorrhage, skeletal
muscle necrosis, tenosynovitis, and fibrinonecrotizing vasculitis. Because these lesions have been
previously described, the following results will consist of more detailed descriptions of some of these
and descriptions of novel lesions. An overview of the various lesions and their time courses are
presented in Figure 2.6.
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Figure 2.5. IRF 3/7 -/- -/- mice sacrificed at 5 DPI. (A) CHIKV inoculated mouse demonstrating
significant swelling of the inoculated foot (left foot; red box). Mild hyperemia is apparent in the
contralateral (right) foot. (B) PBS Sham inoculated mouse demonstrating no swelling associated with
inoculation (left foot).
At 2 DPI, initial evidence of minimal to mild skeletal muscle degeneration was present in 6 of 6
mice (100%). While a fibrinous synovitis has been previously reported in this mouse model145,150, the
full extent and progression of the joint disease has not been described. Initial synovial degeneration
and necrosis was observed at 2 DPI in the inoculated feet in 100% mice, predominantly affecting the
tarsal joints. Two of 6 mice (33%) exhibited variably severe regions of bone marrow necrosis
characterized by locally extensive areas of eosinophilia, loss of cellular detail, accumulation of cellular
debris, and presence of cells with pyknotic, karyolytic or karyorrhectic nuclei (apoptosis and necrosis).

Figure 2.6. Progression of lesions in IRF 3/7 -/- -/- mice infected with chikungunya virus [mice were not
evaluated on Day 3 post-infection].
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By 4 DPI, lesions of skeletal muscle degeneration progressed to necrosis in 5 of 5 mice
(100%). Fibrinoid vasculitis affecting small and medium caliber vessels was apparent in 5 out of 5
mice (100%), though was not widespread. There was necrosis and loss of endothelial cells,
transmural fibrinoid change of the vessel walls, and occasional leukocytoclasia. Inflammatory cells
within the necrotic vessel walls were rare and consisted of degenerate leukocytes. The majority of
joints throughout the foot, including the intertarsal, tarsometatarsal, metatarsophalangeal, and
interphalangeal joints were affected in 100% of mice. In these cases, there was partial to complete
loss of the superficial synoviocytes accompanied by degeneration and necrosis of any remaining
synoviocytes. The subintima was infiltrated by rare neutrophils and mononuclear cells, and variably
effaced and replaced by accumulations of fibrin and necrotic debris. Three of 5 mice exhibited focally
extensive regions of minimal to mild periosteal necrosis characterized by loss of cellular detail and
accumulation of small amounts of fibrin and necrotic debris (Figure 2.7, A). Regions of bone marrow
necrosis were present in 100% of mice (Figure 2.7, B). Occasionally, regions of necrosis also
contained numerous prominent vacuolated macrophages.
By 5 DPI and later, 10 of 10 mice (100%) had extensive multifocal myocyte necrosis
accompanied by minimal infiltration by rare neutrophils and macrophages. In 100% of mice, fibrinoid
vasculitis was widespread and affected the majority of vessels, including occasional larger caliber
vessels. Synovial lesions persisted at these timepoints in all mice (Figure 2.7, E). Additionally, 3 out
of 10 mice (30%) exhibited focal areas of cartilage necrosis located immediately adjacent to regions
of fibrinous synovitis. The cartilage necrosis was characterized by decreased staining intensity of the
cartilage matrix and presence of pale, swollen chondrocytes often exhibiting loss of cellular detail
(necrosis) (Figure 2.7, F). Eight out of 10 mice exhibited focally extensive regions of periosteal
necrosis, particularly evident within the periosteum of the metatarsal bones and all mice (10/10) had
multifocal and extensive regions of bone marrow necrosis. These lesions were present throughout the
foot, often variably affecting numerous bones within the section extending from the tibia to the distal
phalanges. In some instances, necrotic nutrient/mid-diaphyseal vessels were present near the most
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severe regions of bone marrow necrosis, consistent with ischemic necrosis of bone marrow (Figure
2.8, A). Rarely, in the caudal aspect of the calcanei, regions of marrow necrosis extended into and
affected the adjacent physeal cartilage.

Figure 2.7. Metatarsal bones and tarsal joints from IRF 3/7 -/- -/- mice. (A) 4 DPI, periosteal necrosis of
the metatarsal bone (arrowheads). The periosteum is slightly expanded by fibrin and cellular debris.
(B) 4 DPI, distal aspect of metatarsal bone exhibiting extensive bone marrow necrosis. Normal bone
marrow is replaced by fibrin, cellular debris, and necrotic and apoptotic cells. (C) Metatarsal bone
from a PBS-inoculated control mouse demonstrating normal bone marrow and periosteum
(arrowheads). (D) Synovium and articular cartilage from a normal PBS-inoculated control mouse. (E)
5 DPI, fibrinous synovitis exhibiting loss of synoviocytes, accumulation of fibrin along the intima and
within the superficial subintima (arrowhead), and infiltration of the subintima by few leukocytes
(arrows). (F) 6 DPI, cartilage necrosis (bounded by arrowheads) is apparent in the articular cartilage
of the metatarsal bone, adjacent to a region of fibrinous synovitis (arrow). (B = bone, M = skeletal
muscle, BM = bone marrow, S = synovium, JS = joint space, AC = articular cartilage)
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Figure 2.8. Metatarsal bones from IRF 3/7 -/- -/- mice. (A) 7 DPI, fibrinoid vasculitis affecting the middiaphyseal blood vessel of the metatarsal bone (arrow) associated with a region of bone marrow
necrosis. (B) PBS sham inoculated mouse demonstrating normal mid-diaphyseal blood vessel of the
metatarsal bone (arrow). (B = bone, M = skeletal muscle, BM = bone marrow)
In the contralateral feet of all virally inoculated mice, similar, though milder lesions of dermal
edema and hemorrhage, fibrinonecrotizing vasculitis, fibrinous synovitis, and ischemic bone marrow
necrosis were present at similar timepoints. None of the previously described lesions were present in
either the inoculated or contralateral feet of control mice.
2.3.3 Micro-computed Tomography (µCT)
No changes in any trabecular bone parameters in wild-type C57BL/6J mice secondary to
CHIKV infection were identified in either ROI evaluated (Figure 2.9). Within the wild-type C57BL/6J
mice, 3 out of 4 mice (75%) at 21 DPI exhibited periosteal bone proliferation secondary to CHIKV
infection, whereas this same lesion was not identified in any control mice. These lesions were readily
visible on 2D µCT scans (Figure 2.10, A), and 3D reconstructions of the region identified a roughened
surface of the bone (Figure 2.10, B). The first metatarsal bone of each mouse was most consistently
and severely affected in all instances. The regions of periosteal bone proliferation affected between
17.48% and 46.10% of the entire bone length and the volume of the regions of periosteal bone
ranged from 0.0079 mm3 to 0.0812 mm3. The density of these areas ranged from 458.6021 mg
HA/ccm to 631.638 mg HA/ccm as compared to a density of the adjacent cortical bone between
922.7256 mg HA/ccm and 1013.2021 mg HA/ccm, consistent with the fact that immature woven bone
is less dense than mature lamellar cortical bone.
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Figure 2.9. Bone volume/total volume in CHIKV and control mice. ROIs included the proximal
epiphysis of the tibia and distal metaphysis of the femur. Mean + SEM.
No changes were identified in trabecular bone between the two strains. However, several
differences between the two strains were identified in cortical bone at the midshaft of the humerus
(Figure 2.11). IRF 3/7 -/- -/- mice were found to have significantly higher Ct.Th (p=0.010). Ct.Ar/Tt.Ar
also trended towards being significantly higher (p=0.050) in the IRF 3/7 -/- -/- mice, and Ct.Po trended
towards being significantly lower (p=0.050).
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Figure 2.10. µCT scans of a CHIKV infected C57BL/6 mouse at 21 DPI. (A) 2D slice from µCT scan
of the mid-metatarsal region demonstrating region of periosteal bone proliferation (arrows) on first
metatarsal bone (Mt1). (B) Corresponding 3D reconstruction of the plantar metatarsal region of the
same mouse, demonstrating the roughened periosteal surface on Mt1 (arrows) in the region of the
proliferative lesion identified in A.
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Figure 2.11. Comparison of cortical bone parameters in normal control IRF 3/7 -/- -/- and C57BL/6
mice. Specific parameters of interest include cortical bone thickness (Ct.Th), bone area/total area
(BA/TA), and porosity (Ct.Po). Mean + SEM.
40

2.4 DISCUSSION
These experiments demonstrated novel pathologic lesions in the bones and joints of two
established mouse models of chikungunya virus (CHIKV) infection. To our knowledge, this is the first
description of cartilage necrosis associated with CHIKV infection in an adult immunocompetent wildtype animal model, though chondrocyte loss has been recently described in a CCR2 -/- mouse
model129. Additionally, while the presence of CHIKV RNA has been demonstrated in the
periosteum145, the results from the current experiments are the first to demonstrate consistent
periostitis and the presence of periosteal bone proliferation, as well as extensive ischemic bone
marrow necrosis associated with CHIKV infection. These novel lesions offer new insights into the
pathogenesis of acute, chronic, and fatal CHIKV-associated diseases.
It should be noted that different routes of viral inoculation were used in the two mouse models
utilized in these experiments (i.e. intradermal for IRF 3/7 -/- -/- mice and subcutaneous for C57BL/6
mice). Although route of inoculation can have some impact on immunological responses and disease
progression, because early pathogenic mechanisms of viral infection and immune responses are not
compared between the two mouse strains, this difference in technique is not considered to have
significant impact on the importance of the novel lesions described herein. Experiments performed in
our laboratory utilizing a subcutaneous route of infection in IRF 3/7 -/- -/- mice have demonstrated
similar lesions at 5 DPI and later in both the ipsilateral and contralateral feet to those reported here in
intradermally inoculated mice (data not shown). Therefore, the differences in disease manifestations
between the two strains are considered to be predominantly a result of the specific mouse strains
utilized and their different immunological responses to viral infection, rather than differences in
inoculation technique55,119,145,150. As a result of dramatically diminished type 1 interferon response, the
IRF mice develop a severe fatal form of disease and tissues demonstrate paucicellular, primarily
necrotizing changes including severe, widespread fibrinoid vascular necrosis resulting in severe
edema and hemorrhage145,150. This is in contrast to a histiocytic and lymphocytic inflammatory
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response which occurs in the C57BL/6 mice, resulting in a more inflammatory condition and a milder
and more protracted from of disease55,119.
2.4.1 Cartilage – IRF 3/7 -/- -/- and C57BL/6 Mice
Early evidence of articular cartilage necrosis associated with CHIKV infection is significant
because chondrocytes have limited ability to replicate and repair, therefore this damage is often
considered irreversible10,75,136. Attempts at cartilage repair consist of proliferation of fibrocartilaginous
tissue, which will gradually degenerate over time due to differences in biomechanical properties when
compared to normal articular hyaline cartilage10. Therefore, if the initial damage to the articular
cartilage is severe enough, it is often progressive75. Even in the absence of ongoing infection and/or
inflammation, these types of lesions can progress as degenerative changes, similar to those seen in
osteoarthritis186.
2.4.2 Periostitis and Periosteal New Bone – C57BL/6 Mice
As previously mentioned, this report is the first to describe periostitis and periosteal bone
proliferation associated with CHIKV infection in an animal model. Periostitis has been occasionally
described in human cases of CHIKV-associated disease, often affecting the ankles and wrists, and
associated with metacarpophalangeal and proximal interphalangeal stiffness79,138. Additionally,
periostitis accompanied by periosteal bone proliferation associated with tenosynovitis was
demonstrated via radiography in a patient with post-CHIKV infection disease77.
The presence of periostitis with periosteal bone proliferation associated with CHIKV infection
may shed some light on the mechanisms involved in the severe polyarthralgia that occurs with CHIKV
infection both acutely and chronically. The periosteum contains numerous sympathetic nerves and
thus irritation and inflammation result in significant sensation of pain7. Because periostitis often
manifests as painful limbs, particularly as polyarthralgia/polyarthritis when affecting distal extremities,
it can go unrecognized and be misdiagnosed as a myopathy or joint disease, such as rheumatoid
arthritis116. Additionally, while periosteal bone proliferation can be a reversible process107,116, some
areas can persist. These can remain clinically inapparent, but can also interfere with adjacent tendon
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or ligament function resulting in clinical manifestations such as stiffness or discomfort107. The current
experiments suggest that pain associated with both acute and chronic cases of CHIKV-associated
arthralgia may, at least in part, be a result of development of periostitis and periosteal bone
proliferation.
2.4.3 Ischemic Necrosis of Bone Marrow – IRF 3/7 -/- -/- Mice
Another lesion demonstrated in these experiments that may be relevant in regard to severe
and fatal manifestations of CHIKV-associated disease is widespread ischemic necrosis of bone
marrow seen in the IRF 3/7 -/- -/- mice. Clinically, regardless of the inciting cause, bone marrow
necrosis often presents as bone pain (75% of cases) and fever (68.5% cases) in human patients4,78.
Ischemic bone marrow necrosis can progress to true osteonecrosis that ultimately can result in bone
destruction and joint pain54.
It is currently unknown whether ischemic bone marrow necrosis represents a significant
component of severe CHIKV disease in people. This manifestation of disease has not been described
in the literature in humans, possibly because bone marrow biopsies and extensive autopsies
including evaluation of numerous regions of bone marrow are not commonly performed in severe and
fatal cases and/or results of these autopsies may not be reported in the literature. Virus-associated
vasculitis has been reported in cases of CHIKV infection in people, therefore, ischemic necrosis of
tissues including bone marrow is potentially possible50,76,139.
2.4.4 Micro-computed Tomography (µCT)
Results of these experiments that are of additional interest include the lack of significant
differences in measurements of bone volumes in the virally infected C57BL/6J mice as compared to
the negative control mice. It has recently been reported that infection with CHIKV resulted in
significant decreases in various bone parameters, including trabecular bone mass and bone volume
fraction at 3 DPI, as well as increased osteoclastic activity35. However, these findings were not
recapitulated in the current experiments. The most likely reason for this is associated with the ages of
the animals used in the respective experiments.
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In the current experiment, adult, skeletally mature C57BL/6J mice were utilized, as compared
to juvenile (25 day old), skeletally immature C57BL/6 mice used in the previously reported
experiments35. Bone growth, modeling and remodeling dynamics are quite different in juveniles vs.
adults and thus alterations in any of these processes can also be very different depending on the age
of the individual. In experiments utilizing the juvenile model, the authors stated that there was a
decreased width of the growth plates in affected mice, demonstrating potential alterations in bone
growth in addition to increased osteoclastic bone resorption35. Therefore, the results in the immature
mice, in regard to bone dynamics, may not be directly applicable to chikungunya virus disease in
adult humans as active bone growth is no longer occurring. However, it is unclear if these alterations
might be similar to those occurring in neonatal and juvenile cases of CHIKV infection.
The results of the previous experiments, in conjunction with those of the current experiments
suggest it is possible that CHIKV affects bone growth and growth plate function in juveniles and that
there is less of an effect on the mechanics of bone remodeling in an adult animal model. Therefore
the current experiments may more closely replicate disease in adult patients. While decreased bone
volumes were not demonstrated in the current experiments, osteoclastic bone resorption appears to
still be a component of disease. Active osteoclasts were demonstrated in the areas of periosteal bone
proliferation, affecting both the new woven bone as well as the adjacent existing lamellar cortical
bone.
In addition to the analyses performed in regard to CHIKV infection, the normal control IRF 3/7 /- -/-

and wild-type C57BL/6J mice were compared for differences in normal bone structure. The results

indicated that there were significant and near-significant differences in the cortical bone between
these two strains. This indicates that a thorough analysis and understanding of the normal bone
morphology of inbred strains of mice is essential when comparing bony changes, as this may impact
results identified or the underlying mechanisms for changes. Other studies have identified significant
differences in normal bone morphology and remodeling processes among popular mouse strains,
including in both trabecular and cortical bone17,18,80,118,157,172,176. The mechanism(s) involved in the
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differences in cortical bone between the two strains utilized in the current experiments is unknown,
but indicate potential differences in bone growth, modeling and remodeling. Therefore appropriate
choice of mouse strain utilized in studies of bone and joint pathology is essential, and a thorough
evaluation and characterization of skeletal structure is necessary in all experiments.
A potential drawback of this study is that virus and/or viral antigen was not demonstrated within
the tissue sections. Numerous attempts were made to develop an immunohistochemistry protocol
using a commercially available anti-chikungunya virus mouse antibody (LifeSpan BioSciences, Inc.,
Seattle, WA) and Mouse on Mouse peroxidase and fluorescein kits (Vector Laboratories, Burlingame,
CA) (data not shown). Unfortunately, background staining or fluorescence including non-specific
binding of the secondary antibody was observed in these attempts and could not be diminished to a
level at which the authors could be confident in the interpretation of results. However, because
established mouse models were utilized in these experiments and lesions were consistent within
virally inoculated animals while absent in control animals, the novel lesions described herein are still
considered significant.
2.5 CONCLUSIONS
In closing, this study has demonstrated numerous novel findings in bone and joints that may
aid in further determination of the pathogenesis of acute, chronic and severe forms of CHIKVassociated disease. The identification of periostitis and periosteal bone proliferation demonstrates a
component of disease manifestation that may be under-recognized in human cases. Potentially
progressive lesions such as cartilage necrosis and periosteal bone proliferation, and disease
manifestations resulting in permanent tissue alterations, such as fibrosis within skeletal muscle and
synovium, have demonstrated the utility of these mouse models in future studies focusing on chronic
CHIKV-associated disease. These experiments also illustrate the importance of advanced imaging
techniques in evaluation of diseases involving bones and joints, as without the use of µCT, the
presence of some bony lesions may have been overlooked and certainly the extent of these lesions
would not have been fully appreciated.
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Currently, the mechanisms involved in the development of cartilage necrosis, periostitis and
periosteal bone formation, and ischemic bone marrow necrosis are unknown. Experiments examining
the local environment within the joint, including alterations in regulation of cytokine and matrix
metalloproteinase production, may help elucidate the mechanisms involved in CHIKV-associated
cartilage necrosis. A definitive reason for the consistently affected location of the periosteal bone
proliferation is currently unknown, though possibilities could include anatomical structure of the
vasculature within this region or variable severity of inflammation in surrounding tissues. Further
experiments are required for clarification of the factors involved in periostitis and periosteal bone
proliferation and to determine the significance of ischemic bone marrow necrosis associated with
CHIKV infection. Additionally, the incorporation of evaluation via radiographs, CT and MRI into clinical
studies of patients with acute and chronic CHIKV-associated arthralgia will greatly enhance the
current understanding of disease pathogenesis.
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CHAPTER 3: CHARACTERIZATION OF CHRONIC JOINT DISEASE ASSOCIATED
WITH CHIKUNGUNYA VIRUS INFECTION
3.1 INTRODUCTION
Chikungunya virus is an alphavirus spread predominantly by Aedes aegypti and Ae. albopictus
mosquitoes184. The distribution of the virus is subtropical and tropical and it is considered an
emerging infectious disease182. Recently, the virus spread to the Western Hemisphere and there is an
ongoing outbreak affecting 45 countries and territories throughout the Americas and the Caribbean124.
As of June 3, 2016, there have been almost 2 million reported suspected cases and 284 deaths
associated with infection124. Because of the presence of competent mosquito vector species in the
United States, there is a concern for an outbreak occurring in the near future99.
Infection results in disease in 95% of people, and consists predominantly of high fever, rash
and debilitating polyarthralgia usually lasting for 2 weeks6. Additionally, it has been reported that in a
certain percentage of people (14.4-87.2%), chronic or relapsing joint disease can occur, lasting
months to years after resolution of the acute phase of disease141. Unfortunately, due to the lack of an
animal model that demonstrates chronic disease, the mechanisms associated with these
manifestations are currently unknown33. Due to some similarities with rheumatoid arthritis, it has been
suggested that initial infection may result in induction of autoimmune disease6,15. However, the data
currently are lacking to support this hypothesis. Alternatively, others have speculated that persistence
of virus or viral antigen may result in ongoing immune stimulation and continued disease109. In
support of this hypothesis, viral RNA has been demonstrated 16 weeks post infection in a mouse
model, 90 days in a nonhuman primate model, and 18 months in a human synovial biopsy
sample65,71,93.
In regard to the joint disease that occurs following infection, it has recently been reported that
cartilage necrosis, periostitis and periosteal bone proliferation can occur in a mouse model in the
weeks following initial infection60. Unfortunately, cartilage loss cannot be diagnosed definitively via
standard radiographs, and MRI has demonstrated a variable sensitivity for identification of cartilage
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degeneration132. Therefore, substantial progression of disease may be necessary before cartilage
damage is recognized. Additionally, periosteal bone proliferation may be difficult to diagnose by
radiographs in early stages, therefore MRI or CT may be more useful for early detection of periostitis
and periosteal bone proliferation94,149. However, MRI scans are rarely performed during acute stages
of chikungunya virus infection, therefore alternative methods for making these diagnoses would be
useful. As alterations in bone dynamics, such as increases or decreases in bone resorption can be
associated with receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin
(OPG), these may represent serologic parameters that can be measured and associated with disease
manifestations and progressions in a clinical setting179.
Once the onset of skeletal maturity occurs, bone is in a constant state of remodeling. This
includes ongoing bone resorption and bone formation, occurring in a delicate balance to ensure that
one pathway does not outweigh the other and bone homeostasis is maintained. RANKL is a ligand
found on the surface of osteoblasts and when recognized by the RANK receptor on the surface of
osteoclasts, differentiation, proliferation, and activation of osteoclasts is induced164. As osteoclasts
are the cells responsible for bone resorption, increases in RANKL and subsequent RANKL-RANK
interactions, can result in increased bone resorption85. To balance this, OPG is a soluble molecule
with a similar structure to RANK, and acts as a decoy receptor, binding to RANKL, thus preventing
interaction with RANK61. Therefore, increased levels of OPG can result in decreased activation of
osteoclasts, and subsequent decreases in bone resorption85. Perhaps more important than the
individual levels of RANKL and OPG, is their ratio to each other. Alterations in the RANKL:OPG ratio
can result in an imbalance between these processes, whereby a decrease in ratio favors bone
resorption and an increase favors bone protection171.
Therefore, in disease states that result in either new bone formation or bone resorption, it is
possible that significant alterations in serum levels of RANKL, OPG, or both may be detectable. It has
been demonstrated that rheumatoid arthritis patients with active synovitis have increased expression
of RANKL, decreased expression of OPG, and a subsequently increased RANKL:OPG ratio, and
48

these expression levels can be predictive of disease progression45,66,128. Similarly, serum levels of
RANKL and RANKL:OPG ratios can be increased in patients with osteoarthritis, another disease
associated with bone loss128. Because it has been previously demonstrated that there are alterations
in bone and joints associated with CHIKV infection, it is possible that these manifestations may be
associated with changes in the serum levels of RANKL and OPG.
Therefore, the goals of the current experiments were as follows: 1) demonstrate that cartilage
necrosis and periosteal bone formation can be persistent and progressive lesions in chronic stages of
post-CHIKV infection disease, and 2) measure RANKL and OPG levels throughout the disease
process to determine their clinical utility for evaluating disease progression in people. We hypothesize
that 1) cartilage necrosis and periosteal bone proliferation will progress, resulting in continued
cartilage damage and ongoing periostitis in chronic stages of disease, 2) alterations in RANKL, OPG
and RANKL:OPG ratio will be associated with alterations in bone, demonstrating utility for clinical
diagnosis and monitoring. To evaluate these hypotheses, we utilized an established mouse model of
CHIKV infection, an adult C57BL/6 mouse.
3.2 MATERIALS AND METHODS
3.2.1 Virus
A Southeast Asian strain of CHIKV (SVO 476-96) given as a generous gift from the University
of Texas Medical Branch World Reference Center for Emerging Viruses and Arboviruses was used
for all mouse injections. The source of the virus was a human sample in Northeast Thailand from
1996. The original isolate was passaged twice in LLC-MK2 cells followed by one passage in Vero
cells prior to receipt by our laboratory. Subsequently, the virus was passaged an additional time in
Vero cells prior to animal injections.
3.2.2 Ethics Statement
The Louisiana State University (LSU) Institutional Animal Care and Use Committee (IACUC)
approved all methods of animal housing and experimental methods utilized in this study (LSU IACUC

49

protocol #15-005, approved in 2015). The LSU IACUC complies with guidelines of the National
Institutes of Health’s (NIH) Guide for the Care and Use of Laboratory Animals.
3.2.3 Animal Models
For all experiments, C57BL/6J mice (females; >8 weeks of age) obtained from a distributor
were used (The Jackson Laboratory, https://www.jax.org/). Throughout the experiments, mice were
maintained as groups of 4 to 5 individuals in micro-isolator cages in the LSU SVM BSL3 laboratory
and provided with a commercial mouse diet (LabDiet, Land O’ Lakes, Inc., St. Louis, MO) and water
ad libitum. At the time of viral inoculation, mice were anesthetized with isoflurane and intraperitoneal
injection with ketamine (40 mg/kg) and xylazine (2 mg/kg). Once anesthetized, a volume of 10µl of
either 2x104 PFU of virus solution or sterile PBS (negative controls) was injected subcutaneously into
the caudoventral aspect of the hind foot near the tarsal joint.
During experiments, mice were monitored for clinical signs of disease including, but not limited
to lethargy, loss of body weight, joint swelling, and lameness. To minimize pain and suffering
throughout the experiment, if mice lost more than 20% of the initial body weight or exhibited signs of
distress, they were euthanized. No mice met these criteria requiring early euthanasia during the
experiments; so all mice were euthanized at the predetermined timepoints of 30 and 90 days post
inoculation (DPI). Euthanasias were performed using CO2 and subsequent cervical dislocation.
3.2.4 Serology
Prior to euthanasia, mice were anesthetized with isoflurane. Blood samples were obtained via
cardiac puncture with a 23-gauge needle and syringe. Blood samples were allowed to clot at room
temperature for 20 to 30 minutes. Samples were then centrifuged for 10 minutes at 10000 rpm.
Serum samples were subsequently removed using a micropipette, placed in new microcentrifuge
tubes, and frozen at -80C prior to performing ELISAs. Additionally, to examine earlier timepoints (14
and 21 DPI), frozen serum samples from 14 mice from previously reported experiments were
included in this study. Experimental details for these have been previously reported and are similar to
the current experiments60. These samples had been processed similarly to those described above
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and frozen at -80C prior to performing ELISAs. RANKL and OPG were measured using commercially
available ELISA kits following the manufacturer’s instructions (Mouse TRANCE (TNFS11) ELISA Kit
and Mouse OPG (TNFRSF11B) ELISA Kit, Thermo Scientific™ Pierce™, Waltham, MA, USA).
3.2.5 Microcomputed Tomography (µCT)
After euthanasia, whole mice were fixed for a minimum of 48 hours in 10% neutral buffered
formalin. For µCT scanning, intact hindlimbs from all mice were collected. The region of interest for
scans was the distal hindlimb from the proximal region of the tuber calcanei to the distal phalanges.
Prior to evaluation, specimens were placed in proper holders in 70% ETOH and samples were then
scanned by µCT (Scanco model 40; Scanco Medical AG, Basserdorf, Switzerland). Scans were
performed in the transverse plane at 55kV, 0.3-second integration time, with a 16 µm resolution. For
qualitative evaluation of overall bone morphology utilizing 3D reconstructions, proper thresholds were
tested. The appropriate threshold was then utilized throughout the study for all specimens.
3.2.6 Histopathology
After the µCT scans were performed, fixed specimen were processed for histologic evaluation,
which included transverse (30DPI) or sagittal (90 DPI) sectioning of the inoculated hind foot followed
by decalcification in 10% EDTA for 3-4 weeks. Subsequently, routine processing for histologic
evaluation was performed, including dehydration in increasing concentrations of ethanol and paraffin
wax embedding. Sections of 4-5 µm thicknesses were adhered to glass slides and routinely stained
with hematoxylin and eosin (H&E). For histologic assessment, the entire tissue sections were
evaluated for pathologic changes throughout the hind foot, with particular attention paid to skeletal
muscle, joints and bones. Additionally, a semi-quantitative Articular Cartilage Structure (ACS) score
was determined for each section in the 90 DPI control and virus treatment groups. For consistency,
evaluations were performed on the proximal intertarsal joint (articulation of the talus and central tarsal
bone) of each mouse. An established ACS scoring system was utilized for these evaluations, as
previously described113. This system assigns a score of 0 to 12 based on severity of cartilage
necrosis, clefting, and area affected. A board-certified veterinary anatomic pathologist performed the
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histologic evaluations (BAG). Microscopic evaluations were performed utilizing a Nikon Eclipse Ni-U
upright microscope (Nikon Instruments Inc., Melville, New York) with an attached Olympus DP72
microscope digital camera (Olympus Corporation, Tokyo, Japan) for image capture.
3.2.7 Immunohistochemistry
Tissue sections were routinely deparaffinized in xylene and rehydrated in decreasing
concentrations of alcohol. An antigen retrieval step was performed using a high temperature citratebased technique (Vector® Antigen Unmasking Solution, Vector Laboratories, Inc., Burlingame, CA,
USA). This was followed by an endogenous peroxidase-blocking step utilizing BLOXALL (Vector
Laboratories, Inc., Burlingame, CA, USA). For identification of CHIKV antigen in tissue sections, a
primary anti-chikungunya virus rabbit antibody (IBT Bioservices, Gaithersburg, MD, USA), and a
commercially available reagent detection kit (ImmPRESS Reagent Anti-Rabbit Ig Peroxidase kit) and
a peroxidase substrate kit (ImmPACT DAB Peroxidase Substrate kit) from Vector Laboratories, Inc.
(Burlingame, CA, USA) were utilized, following the manufacturers instructions. This was followed by
counterstaining with hematoxylin (Vector® Hematoxylin QS, Vector Laboratories, Inc., Burlingame,
CA, USA).
3.2.8 Statistics
All statistical analyses were performed using a commercially available statistical software
package (IBM SPSS Statistics version 23, IBM Corp., Armonk, New York, USA). For purposes of
analyses, 14 and 21 DPI were grouped and analyzed together and 30 and 90 DPI were grouped and
analyzed together because these experiments were performed at separate times and had different
sample sizes and variances. Data were examined for outliers prior to analyses; any data points that
were more than 2.2 interquartile ranges below the first quartile or above the third quartile were
considered outliers and were removed prior to analyses. This resulted in the removal of one CHIKVinfected mouse from the 90 DPI treatment group. ANOVAs were then performed on both data groups
to determine significances. For ACS scores of 90 DPI mice, a Mann Whitney U analysis was
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performed to determine differences in ACS score distribution between the control and virus treatment
groups.
3.3 RESULTS
3.3.1 Histology
At 30 DPI, six of six (100%) mice had evidence of ongoing myositis and skeletal muscle
regeneration, similar that previously reported at 21 DPI60. Five of six mice (83.3%) demonstrated
ongoing chronic synovitis characterized by mild synovial hyperplasia and hypertrophy accompanied
by inflammatory infiltrates composed predominantly of lymphocytes and fewer macrophages. Similar
inflammatory infiltrates were seen within tendon sheaths in six of six mice (100%). In three of six mice
(50%) there was evidence of ongoing periosteal disease consisting of mild periosteal hypercellularity
and periosteal bone proliferation, similar to that previously reported at 21 DPI (Figure 3.1, A). Rarely,
there were also osteoclasts actively resorbing subperiosteal new bone and mature cortical bone.
Because histologic samples were sectioned differently (in cross-section) at this timepoint to facilitate
thorough evaluation of the periosteal bone, articular cartilage could not be assessed. There were no
significant findings in any of the control mice at this timepoint.
At 90 DPI, five of seven mice (71.4%) displayed minimal to mild myofiber dropout with
replacement fibrosis. Six of seven mice (85.7%) demonstrated a concurrent ongoing synovitis, while
seven of seven mice (100%) exhibited ongoing chronic enthesitis (Figures 3.1, B and C). In all cases,
inflammatory infiltrates were composed predominantly of lymphocytes with fewer macrophages and
plasma cells, and mild synovial hypertrophy and hyperplasia were present. None of the mice (0%)
showed any evidence of periostitis or periosteal bone proliferation. All mice (100%) in both the virus
and control groups had some degree of articular cartilage abnormalities, ranging from minimal
surface irregularities to full thickness fibrillation and/or clefting of the cartilage. Four of seven mice
(57.1%) in the virus group exhibited cartilage clefting as compared to one (14.3%) in the control group
(Figure 3.1, D). A Mann Whitney U test demonstrated that the distribution of the ACS scores were
significantly higher in the virally infected group (median = 11) as compared to the PBS control group
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(median = 4)(p=0.011) indicating more severe cartilage damage associated with viral infection. There
were no additional significant findings in any of the control mice at this timepoint.

Figure 3.1. Histopathologic lesions of bones and joints in CHIKV infected mice. (A) Metatarsal bone
from a 30 DPI CHIKV infected mouse demonstrating periosteal bone proliferation (arrows) and
hypercellular periosteum (periostitis) (arrowheads). (B) Synovium from a 90 DPI CHIKV infected
mouse demonstrating inflammatory infiltrates in the subintima composed predominantly of
lymphocytes and fewer macrophages and plasma cells (synovitis) (arrows) and hypertrophic
synoviocytes (arrowheads). (C) Tarsal bone and associated enthesis from a 90 DPI CHIKV infected
mouse demonstrating inflammatory infiltrates composed of predominantly lymphocytes and fewer
macrophages and plasma cells (enthesitis) (arrows). (D) Proximal intertarsal joint from a 90 DPI
CHIKV infected mouse demonstrating ongoing damage to the articular cartilage including surface
irregularities (arrowhead) and cartilage clefting with flap formation (arrow).
3.3.2 Immunohistochemistry
The immunohistochemical results were similar at 21, 30, and 90 DPI. Scattered throughout the
dermis, there were numerous round to oval immunopositive cells with morphology resembling
macrophages and/or dermal fibroblasts (Figure 3.2, A). There were morphologically similar
immunopositive cells scattered within regions of inflammation surrounding some tendons, and
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throughout the subintima of the synovium, though there was no apparent positivity within the
synoviocytes themselves (Figure 3.2, B, C, and D). Rarely, there were also scattered ovoid to
fusiform immunopositive cells within the perimysium surrounding skeletal muscle bundles. Due to the
quality of the tissue sections, it could not be definitively determined if there was CHIKV antigen
present within cartilage, bone or periosteum.

Figure 3.2. Immunohistochemistry for CHIKV antigen on tissue sections. (A) Dermis from a CHIKV
infected mouse at 21 DPI. There are numerous immunopositive round to ovoid cells scattered
throughout the dermis (arrows), morphology consistent with macrophages and/or dermal fibroblasts.
(B and C) Synovium from a CHIKV infected mouse at 21 DPI and 30 DPI, respectively, demonstrating
numerous immunopositive round to ovoid cells within the subintima of the synovium (arrows),
morphology consistent with macrophages and/or fibroblasts. There is no positivity within the adjacent
hyperplastic synoviocytes (arrowheads). (D) Synovium from a CHIKV infected mouse at 90 DPI
demonstrating numerous immunopositive round to ovoid cells within the subintima of the synovium
(arrows), morphology consistent with macrophages and/or fibroblasts.
3.3.3 Micro-computed Tomography (µCT)
At 30 DPI, there was periosteal new bone proliferation on the distal plantar aspect of the first
metatarsal bone (3 out of 6 [50%] of virally infected mice) (Figure 3.3). There was no evidence
periosteal bone proliferation present at 90 DPI.
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Figure 3.3. 2D slice from µCT scan of the mid-metatarsal region from a 30 DPI CHIKV infected
mouse demonstrating region of periosteal bone proliferation (arrowheads) on first metatarsal bone
(Mt1).
3.3.4 Serology
At 14 and 21 DPI, there were no significant differences in RANKL, OPG, or RANKL:OPG ratio
at any timepoint between the control and virus groups (Figures 3.4, A, C, and E). The RANKL of the
30 DPI control group was significantly higher than the 90 DPI virus group (p=0.002)(Figure 3.4, B).
The OPG in the 30 DPI virus group was significantly lower than the 90 DPI virus group (p=0.003)
(Figure 3.4, D). The RANKL:OPG ratios of the 30 DPI control and 30 DPI virus groups were both
significantly higher than the 90 DPI virus group (p=0.002 and 0.017, respectively)(Figure 3.4, F).
Additionally, the ratio of the 90 DPI control group was higher compared to the 90 DPI virus group, and
this difference approached significance (p=0.083).
3.4 DISCUSSION
These experiments demonstrated continued and permanent tissue damage at 90 DPI
associated with CHIKV infection. Chronic synovitis remains at this timepoint and there is clear
permanent damage to the cartilage seen in the majority of mice. However, these experiments also
demonstrated that periosteal bone proliferation associated with infection, though present at 30 DPI,
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has completely resolved by 90 DPI, indicating that this disease manifestation is reversible. Of
additional significance, there are alterations in serum levels of RANKL, OPG, and the RANKL:OPG
ratio at later timepoints, demonstrating their potential utility in a clinical setting for evaluation of
chronic cases of CHIKV-induced arthralgia.

Figure 3.4. Serologic measurements of RANKL, OPG and RANKL:OPG ratio for mice at various
timepoints. DPI = days post inoculation, PBS = PBS control mice, CHIKV = chikungunya virus
infected mice. Mean + SEM. Horizontal bars denote significant differences.
Presence of synovitis in chronic stages of post-CHIKV infection-associated disease has been
previously reported in a juvenile C57BL/6 mouse model119. Caution should be taken when utilizing
juvenile animal models for specific purposes of studying diseases associated with bones and joints as
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these animals have immature skeletons and thus, alterations may not necessarily reflect disease
manifestations in a skeletally mature patient19. Therefore, the current studies have confirmed that
chronic synovitis also occurs in an adult animal model and are thus relevant for studying bone and
joint manifestations associated with chronic CHIKV disease. Additionally, these experiments have
demonstrated that there is persistence of viral antigen associated with the ongoing synovitis,
demonstrating a potential mechanism for continued joint disease. Although viral persistence has been
previously demonstrated in a mouse model65, the location of virus or viral antigen has not been
determined. In the current experiments, viral antigen has been demonstrated in macrophages and/or
fibroblasts within the dermis, peritendinous tissues, and the synovial subintima. This corroborates
previous evidence that has demonstrated persistence of CHIKV antigen in the synovium of a patient24
and virus in synovial macrophages in NHPs93. The presence of persistent viral antigen and synovitis
can be associated with ongoing joint pain and thus demonstrates a potential mechanism for chronic
arthralgia seen in some patients100.
Interestingly, while true synovitis was seen in 85.7% of virus-infected mice, 100% of mice
demonstrated chronic enthesitis at 90 DPI. Although chronic CHIKV-associated arthritis has been
compared to rheumatoid arthritis due to a number of clinical similarities, enthesitis is not considered a
common finding in RA, but rather is more common in some of the spondyloarthropathies which are
most often associated with axial skeletal disease such as sacroiliac pain16,79,146. Though chronic
CHIKV-associated joint disease is most commonly described as affecting joints of the appendicular
skeleton, axial pain has been described in 28-32% of cases as well181. Therefore, chronic CHIKVassociated arthritis may have a more broad spectrum of clinical presentations than is commonly
recognized for cases of autoimmune arthritis such as RA. In fact, in some reports regarding chronic
CHIKV-associated arthralgia, patients met the criteria to be diagnosed with various chronic
inflammatory rheumatisms, such as rheumatoid arthritis, spondyloarthropathy, and undifferentiated
polyarthritis, indicating that this may represent a heterogeneous group of disorders and/or disease
manifestations79. It should also be noted that the pain associated with enthesitis is considered to be
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severe and debilitating, sometimes lasting for years47, similar to what is described in cases of CHIKVassociated arthralgia. As enthesitis requires advanced imaging such as MRI or ultrasound112, this
may be an underappreciated component of sources of pain and disease in CHIKV patients,
particularly in the chronic stages.
Additionally, the finding of continued and progressive cartilage damage at 90 DPI indicates
another potential mechanism that may occur in some chronic cases of CHIKV-induced joint disease.
While there were cartilage lesions seen in both the control and virally infected groups, the severity of
lesions was significantly higher in the virally infected mice. The presence of the cartilage lesions seen
in both treatment groups is likely a result of degenerative changes associated with naturally occurring
osteoarthritis. At the 90 DPI timepoint, these mice were 24.6 weeks old and C57BL/6 mice are
reported to have relatively high incidences of spontaneous development of osteoarthritis, visible by 16
weeks of age14,110. Although these degenerative changes were seen in both treatment groups, they
were significantly more severe in the virally infected group, suggesting that viral infection may
exacerbate these lesions in the articular cartilage. The cartilage degeneration and necrosis that has
been previously reported in this mouse model60 has progressed to more severe disease at 90 DPI
including cartilage thinning, fibrillation and necrosis.
Chondrocytes have only minimal abilities to replicate and repair, therefore the lesions
described in the current experiments represent irreversible and progressive damage to the articular
cartilage10,75,136. Additionally, it should be noted that presence of cartilage flaps resulting in full
thickness loss of cartilage indicates that alterations in subchondral bone (i.e. sclerosis) will follow186.
Because there are currently no effective treatments for reversing damage to articular cartilage, this
indicates that prevention of this disease manifestation is essential, as the initial cartilage damage
occurs during the acute to subacute stages of infection60.
Conversely, though periosteal bone proliferation can in some instances be a progressive
condition108, the current experiments demonstrated that the bone proliferation seen in this mouse
model has completely resolved by 90 DPI. Therefore, while this manifestation may have clinical
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significance during the acute phase of disease, continued pain associated with periostitis and
periosteal bone proliferation likely does not occur in this model. However, it should be recognized that
standard treatment options for pain associated with acute and subacute stages of CHIKV-infection
generally rely on the use of NSAIDs, which can often be ineffective for treating pain associated with
periostitis and periosteal bone proliferation161. Therefore, alternative treatment options may be worth
investigating, including bisphosphonates such as pamidronate and zoledronic acid which are often
used in cases of severe pain associated with periosteal disease11,121.
Of additional interest are the RANKL, OPG, and RANKL:OPG ratio results. It has been
reported in a juvenile mouse model of CHIKV infection that significant decreases in bone density by 3
DPI and an associated increase in the RANKL:OPG ratio favoring bone resorption occur35. However,
we have previously reported that significant decreases in bone density do not occur in this adult
mouse model of disease60. As previously mentioned, care must be taken when using a skeletally
immature animal model to study bone and joint disease, as bone dynamics can be quite different in
skeletally mature animals. Because significant alterations in bone density do not occur at 14 and 21
DPI, it is not surprising that there was also no alteration in RANKL or OPG at these timepoints.
However, there was a significantly decreased RANKL:OPG ratio at 90 DPI associated with
viral infection, as compared to the negative control and the virally infected group at 30 DPI, and a
trend towards significance when compared to the negative control group at 90 DPI (Figure 3.3, F).
These alterations in serological parameters would result in an overall favoring of bone protection
rather than bone resorption. In other words, there would likely be less bone resorption occurring in the
virally infected mice at 90 DPI when compared to those at 30 DPI, and to the 30 DPI and 90 DPI
control mice.
There are several possible reasons for these alterations at this timepoint in the disease. This
could correspond to repairs from the damage done at earlier timepoints. At 21 DPI, we have
previously reported osteoclastic bone resorption of both the periosteal new bone and the normal
cortical bone60, which was also observed at 30 DPI. Though bone resorption would be necessary to
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resolve the periosteal new bone proliferation, bone formation would also need to occur in order to
repair the resorption that occurred in the cortical bone. It would be very interesting to look at
additional timepoints between 30 and 90 DPI, because there may be a stage during which bone
resorption is favored to resolve the bone proliferation, followed by a shift towards bone protection at a
later timepoint, to stop the resorption and favor formation to resolve any damage to the cortical bone.
Additionally, it has been reported that increased levels of OPG and subsequent reduction in
the RANKL:OPG ratio have been associated with decreased activation of endosteal osteoclasts, but
not periosteal osteoclasts, suggesting that alterations in the RANKL:OPG pathways may not have as
strong an impact on periosteal bone resorption82. Therefore, it is possible a decreased RANKL:OPG
ratio may allow resorption of the periosteal new bone, while protecting against osteoclastic bone
resorption within the endocortical space. Further investigations may determine if there is a clinical
utility to these alterations in RANKL:OPG ratio. The current experiments indicate that there is a
decrease in RANKL:OPG ratio throughout the course of disease, the timing of which coincides with
complete resolution of the periosteal bone proliferation. Therefore, it is possible that serum levels of
RANKL and OPG could be tracked during acute to subacute stages of disease to determine when
these aspects of disease are resolving, thus aiding in treatment decisions.
In addition to examining timepoints between 30 and 90 DPI, future studies should focus on
later timepoints to continue tracking and evaluating the ongoing synovitis and cartilage damage.
Currently, there are no established animal models of chronic CHIKV-associated joint disease that
demonstrate cartilage loss and bony lysis believed to occur in human cases69,167. However, the
presence of synovitis at 90 DPI, in conjunction with significant cartilage damage and loss, suggests
that disease could continue to progress in this mouse model. It would be interesting to examine later
timepoints to determine if the synovitis ultimately resolves and evaluate progression of cartilage
lesions and potential changes in underlying subchondral bone. If these lesions in fact progress, it is
possible that alterations in the subchondral bone such as sclerosis and/or bony lysis could also
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occur95,156. Therefore, the animal model utilized in the current experiments has potential utility for
studying more chronic CHIKV-associated bone and joint disease.
Furthermore, because we have demonstrated persistence of CHIKV antigen associated with
synovitis and ongoing cartilage damage, experiments examining mechanisms of the cartilage
changes can be performed. Loss of proteoglycans and subsequent cartilage degeneration and
necrosis can be a result of ongoing synovitis and production of matrix metalloproteinases (MMP) by
synoviocytes84,154 and some pro-inflammatory cytokines (such as IL-1β and TNF-α)59,131. Additionally,
chondrocyte apoptosis can be considered a mechanism of cartilage damage187, and CHIKV has been
shown to induce apoptosis in various cell types46,83,92,180,183. Therefore, evaluation of local expression
of these cytokines and the potential for chondrocyte apoptosis could help elucidate specific
mechanisms of cartilage damage associated with CHIKV infection.
In addition, examining serological markers of bone formation such as bone alkaline
phosphatase and osteocalcin, or examining alterations in bone morphogenic protein expression
would be helpful, particularly at the earlier timepoints when active bone formation is occurring.
Serological parameters associated with bone formation could correlate with the periosteal bone
proliferation seen at the 3 to 4 week timepoint and thus, could be useful in a clinical setting for early
identification of these manifestations of disease.
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CHAPTER 4: CHIKUNGUNYA VIRUS INFECTION ALTERS NEW BONE
FORMATION ASSOCIATED WITH PROGRESSION OF PRE-EXISTING
OSTEOARTHRITIS
4.1 INTRODUCTION
Chikungunya virus (CHIKV) is an RNA virus in the alphavirus group, which includes both the
New (encephalitic) and Old (arthritogenic) alphaviruses126. It is spread by mosquitoes, predominantly
Aedes aegypti and Ae. albopictus, and can be found throughout tropical and subtropical regions,
resulting in potential risk to over 1 billion people182. Recently, in October of 2013, an outbreak began
in the Caribbean and has subsequently spread throughout Central and South America, resulting in
almost 2 million reported suspected cases124. This represents the first major outbreak in the western
hemisphere and currently affects 45 countries and territories124. There have been 3490 reported
cases in the United States since the outbreak began, including 12 locally acquired cases in Florida in
201429,30. There were an additional 4912 cases in US territories (Puerto Rico, the US Virgin Islands,
and America Samoa), the majorities of which were locally acquired cases29,30.
The vast majority of people that become infected after a mosquito bite will develop disease,
consisting predominantly of high fever, extensive rash and debilitating polyarthralgia, for which the
virus was named6. Chikungunya is a Tanzanian Makonde word roughly translated as “that which
bends upward”, and refers to the extensive joint distortion as a result of severe pain associated with
infection116. This debilitating polyarthralgia can last for weeks in many people, who are often
bedridden as a result. Additionally, in 12-82% of cases, it has been reported that an ongoing or
chronic arthralgia and/or arthritis can occur following resolution of the initial acute phase of
disease25,52,151,160,181. The mechanisms associated with development of these chronic forms of
disease are currently unknown. However, it has been recently reported that infection with CHIKV in
mouse models of disease can result in cartilage necrosis, periostitis, and periosteal bone proliferation,
indicating potential avenues for ongoing joint disease60. Additionally, more severe acute arthralgia
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and ongoing chronic arthritis associated with CHIKV infection have been correlated with pre-existing
joint disease, such as osteoarthritis (OA)151,160.
It is estimated that 22.7% (52.5 million) of adults in the United states have been diagnosed
with OA and nearly half of these have subsequent reduction in mobility or activity28. Furthermore, by
the year 2030, estimates indicate that 67 million adults (25% of the US population) will have clinically
diagnosed arthritis28. Thus, OA is a widespread problem in the United States, indicating a very real
risk that people infected with CHIKV may have an underlying pre-existing joint disease at the time of
infection.
Joint damage, particularly that which involves the articular cartilage, is considered to be
irreversible75. Therefore, current treatment regimens are centered on alleviating symptoms, rather
than repairing current damage or preventing future damage97,148,189. As cartilage loss has been
demonstrated in both OA and more recently in CHIKV-induced disease60, a more thorough
understanding of the interactions of these diseases is required to prevent severe irreversible damage
within the joint. In addition to cartilage necrosis, alterations in bone occur as OA progresses. Changes
vary depending on the stage of disease, but can include increases in subchondral bone and formation
of periarticular osteophytes49,74,89. Some of these changes in bone have been linked to alterations in
receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG)166.
RANKL and OPG are intimately involved in bone homeostasis, specifically in regard to
regulating bone resorption. RANKL is expressed on the surface of osteoblasts and when it interacts
with RANK on the surfaces of osteoclast precursors, it induces their differentiation, proliferation and
activation164. In order to regulate this pro-bone resorption pathway, a soluble decoy receptor (OPG)
binds to RANKL, blocking its ability to interact with RANK61. In some instances of OA, it has been
demonstrated that alterations in RANKL and OPG expression within the subchondral bone could
result in a shift towards bone formation, rather than bone resorption, and in fact, these alterations in
the RANKL:OPG ratio corresponded to increased subchondral bone thickness166. Conversely, it has
been demonstrated that CHIKV infection can result in increases in the RANKL:OPG ratio which may
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favor bone resorption35. As a result, there may be conflicting changes in RANKL and OPG associated
with CHIKV infection as compared to OA, and the potential interactions between these alterations are
unknown.
Therefore, the goals of these experiments were to 1) determine if infection with CHIKV would
result in more rapid progression of pre-existing OA, and 2) identify any alterations in RANKL and
OPG that may be related to alterations in bone remodeling dynamics and disease manifestations in
CHIKV associated disease, OA, and concurrent CHIKV arthritis and OA. We hypothesize that 1)
concurrent CHIKV infection will result in more severe cartilage necrosis and synovitis, and alterations
in bone formation associated with pre-existing OA, and 2) differences in disease manifestations and
severity will be associated with alterations in RANKL and OPG. To address this hypothesis, we
utilized an established mouse model of surgically induced OA (destabilization of the medial meniscus
surgical technique [DMM]) in a mouse strain also established as a model of CHIKV infection, the
C57BL/6 strain55,57,60,113.
4.2 MATERIALS AND METHODS
4.2.1 Virus
A Southeast Asian strain of CHIKV (SVO 476-96) initially isolated from a human sample in
Northeast Thailand in 1996 was utilized for all mouse inoculations. This isolate was given as a
generous gift from the University of Texas Medical Branch World Reference Center for Emerging
Viruses and Arboviruses. After initial collection, the virus was passaged twice in LLC-MK2 cells and
once in Vero cells. After our laboratory received the isolate, the virus was passaged again in Vero
cells before utilization in experiments.
4.2.2 Ethics Statement
All animal housing and experimental methods in this study were approved by the Louisiana
State University (LSU) Institutional Animal Care and Use Committee (IACUC) (LSU IACUC protocol
#15-005 approval in 2015) in compliance with the guidelines of the National Institutes of Health’s
(NIH) Guide for the Care and Use of Laboratory Animals.
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4.2.3 Animal Models
Adult (12 weeks of age), female C57BL/6J mice were obtained from a distributor (The Jackson
Laboratory, https://www.jax.org/). Mice were housed in the LSU SVM BSL3 laboratory in microisolator cages in groups of 4 to 5 individuals. All mice had ad libitum access to water and a
commercial mouse diet (LabDiet, Land O’ Lakes, Inc., St. Louis, MO, USA) throughout the
experiments.
4.2.3.a Destabilization of the Medial Meniscus (DMM) Surgeries
Immediately prior to surgeries, mice were given subcutaneous injections of gentamicin
(5mg/kg, diluted in 0.1ml sterile saline) and carprofen (5mg/kg, diluted in 0.1ml of sterile saline). Mice
were subsequently maintained under anesthesia using isoflurane. DMM surgeries were performed on
the stifle of the right hindlimb of all DMM mice (virus and controls) as previously described57. Briefly,
parasagittal skin incisions were made on the craniomedial aspect of the stifle joint, just medial to
midline. The patellar ligament was visualized, retracted laterally and the medial meniscal ligament
was transected. The joint capsule and skin incision were closed using 5-0 coated VICRYL®
(polyglactin 910) suture (Ethicon USA, LLC, Somerville, NJ, USA), followed by closure with a wound
clip (BD BBLTM AUTOCLIP wound clips, Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
Mice were monitored daily following surgeries; additional gentamicin and carprofen injections were
given post-op at 24 and 48 hours, and 12 and 24 hours, respectively. Wound clips were removed 7
days after surgery, though some mice had removed their wound clips prior to this. Previous
experiments performed by one of the authors (MAM) have demonstrated that Sham surgeries
consisting of surgical incision and routine closures resulted in no significant alterations in the joints;
therefore Sham groups in the current experiments only received intra-articular injections (see below).
4.2.3.b Viral Inoculations
Following the DMM surgeries, mice were allowed to recover for a period of 1 week before
receiving intra-articular injections. During experiments and prior to viral inoculation, mice were initially
anesthetized with isoflurane followed by intraperitoneal injection with ketamine (40 mg/kg) and
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xylazine (2 mg/kg). Subsequently, mice were intra-articularly injected in the medial aspect of the right
stifle joint with 10µl of either 2x104 PFU of virus solution, sterile PBS (8 week post-DMM negative
controls) or Vero cell culture media (4 week post-DMM negative controls). The experiments included
the following treatment groups: at the 4 week post-surgery/3 week post-inoculation timepoint, there
were 4 treatment groups consisting of virally inoculated and control inoculated mice that had received
the DMM surgery (DMM+CHIKV and DMM+Media, respectively), and virally inoculated and control
inoculated mice that received no surgery (Sham+CHIKV and Sham+Media, respectively); at the 8
week post-surgery/7 week post-inoculation timepoint, there were 3 treatment groups consisting of
virally inoculated and control inoculated mice that had received the DMM surgery (DMM+CHIKV and
DMM+PBS, respectively), and virally inoculated mice that received no surgery (Sham+CHIKV).
Throughout the entire experimental timeframes, mice were monitored for clinical signs of
disease such as lethargy, lameness, joint swelling, or loss of body weight. If more than 20% of the
initial body weight was lost or signs of pain or distress were observed during experiments, mice would
be immediately euthanized to minimize pain and suffering. However, none of the mice in these
experiments met any of these criteria, therefore all mice were euthanized at the predetermined
experimental timepoints (4 weeks and 8 weeks post-surgery/3 and 7 weeks post-inoculation). All mice
were euthanized via asphyxiation in a CO2 chamber, followed by cervical dislocation.
4.2.4 Serology
For blood sample collections, mice were initially anesthetized with isoflurane. Samples were
collected via cardiac puncture with a 23-gauge needle and syringe. Mice were then euthanized as
described above. Blood samples were transferred to microcentrifuge tubes and allowed to clot at
room temperature for 20 to 30 minutes. Subsequently, clotted blood samples were centrifuged for 10
minutes at 10000 rpm, after which serum was removed using a micropipettor and placed in new
microcentrifuge tubes. Prior to performing ELISAs, serum samples were frozen and stored at -80C.
For analyses, samples were allowed to thaw at room temperature and commercially available ELISA
kits for RANKL and OPG were performed, following the manufacturer’s instructions (Mouse TRANCE
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(TNFS11) ELISA Kit and Mouse OPG (TNFRSF11B) ELISA Kit, Thermo Scientific™ Pierce™,
Waltham, MA, USA).
4.2.5 Microcomputed tomography (µCT)
Immediately following euthanasia, mice were fixed in 10% neutral buffered formalin for a
minimum of 48 hours. All µCT scans were performed on intact hindlimbs and the region of interest
consisted of the stifle joint extending from approximately mid-shaft of the femur to mid-shaft of the
tibia and fibula. Hindlimbs were placed in holders in 70% ETOH and scanned using a bench top µCT
scanner (Scanco model 40; Scanco Medical AG, Basserdorf, Switzerland). Samples were oriented for
scanning in a transverse plane and the following scanning parameters were used: 55kV, 0.3-second
integration time, and a resolution of 8 µm.
Prior to analyses, all scans were examined to determine proper thresholds for evaluation of
osteophyte and subchondral bone volume (BV) and total volume (TV), and for 3D reconstructions to
evaluate overall bone morphology. These thresholds were tested for each specimen and the same
thresholds were used throughout the study. Established procedures and nomenclature were used for
all variables16.
4.2.6 Histopathology
After µCT evaluations were performed, the right stifle joints including distal femur and proximal
tibia and fibula were decalcified in 10% EDTA. Routine processing for histologic evaluation was
performed on all samples. This included dehydration in increasing concentrations of ethanol and
embedding in paraffin wax. This was followed by adherence of 4-5 µm thick sections to glass slides
and routine staining with hematoxylin and eosin (H&E) for evaluation. Serial sections were also
obtained and stained with Safranin O to evaluate articular cartilage. Histologic evaluations were
performed by a board-certified veterinary anatomic pathologist (BAG) and an orthopedic researcher
experienced in evaluation of osteoarthritic joints (MAM), who were blinded to treatment groups. A
Nikon Eclipse Ni-U upright microscope (Nikon Instruments Inc., Melville, New York) was utilized for
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microscopic evaluations. An attached Olympus DP72 microscope digital camera (Olympus
Corporation, Tokyo, Japan) was utilized for digital image capture.
Presence or absence and severity of synovitis in samples was assessed using a modified
version of the grading system described by Krenn et al.90. Total synovitis scores (TSS) were
determined separately for the synovial cells, inflammation and synovial stromal activation. Eight
regions of the synovium here evaluated to determine hyperplasia scores (0-3) after which these
results were averaged to determine the mean score; the maximum hyperplasia score was also
determined (0-3). For inflammation, a score of 0-3 was determined for inflammatory cell infiltrates and
a separate score of 0-3 for presence of fibrin and/or fibrinoid necrosis. An additional 0-3 score was
determined for synovial stromal activation. All scores were then combined to determine a total
synovitis score (0-15). Additionally, histologic assessment included determination of a Safranin-O
staining score, as previously described113. Histomorphologic assessments were performed on the 8
week post-surgery groups only, using an OsteoMeasure bone histomorphometry system
(OsteoMetrics, Atlanta, GA) as previously described113. Evaluated parameters included articular
cartilage area (AC.Ar) and thickness (AC.Th), subchondral bone area (SCB.Ar) and thickness
(SCB.Th), chondrocyte cell death area (CCD.Ar), proportion of dead chondrocytes (CCD/AC),
chondrocyte number (Chond#) and area of abaxial osteophytes (Ab.OP).
4.2.7 Statistics
SPSS statistics version 23 was used for all analyses (IBM SPSS Statistics, IBM Corp.,
Armonk, New York, USA). Data from 4 week and 8 week post-surgery mice were analyzed separately
as the experiments were performed at different times and there were slight differences in treatments
(i.e. sham inoculations utilized cell culture media for the 4 week groups and sterile PBS for the 8
week groups). ANOVAs were performed for RANKL, OPG, RANKL:OPG ratio, histomorphometry,
and µCT data. Kruskal Wallis tests were performed for the Total Synovitis Scores (TSS).
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4.3 RESULTS
4.3.1 Serology
4.3.1.a RANKL
At 4 weeks, in the groups that did not undergo the DMM surgery, RANKL was significantly
increased in the virally infected mice (Sham+CHIKV) compared to the control group (Sham+Media)
(p=0.006), indicating an increase in RANKL associated with viral infection (Figure 4.1, A). However, in
the groups that received DMM surgery, there was no significant difference between the virally
infected mice and the control group. There was a significant difference between the Sham+CHIKV
group and the DMM+Media group (p=0.001). At 8 weeks, there were no significant differences
between any of the groups (Figure 4.1, B).
4.3.1.b OPG
At 4 weeks, the only significant result was a lower OPG level in the Sham+CHIKV group as
compared to the DMM+Media group (p=0.007) (Figure 4.1, C). Similarly, within the 8-week groups,
the Sham+CHIKV group had a significantly lower OPG than the DMM+PBS group (p=0.004) (Figure
4.1, D).
4.3.1.c RANKL:OPG Ratio
At 4 weeks, the RANKL:OPG ratio was significantly higher in the Sham+CHIKV group than in
all other groups (vs. Sham+Media, p=0.000; vs. DMM+Media, p=0.000; vs. DMM+CHIKV, p=0.001)
(Figure 4.1, E). At 8 weeks, there were no significant differences between any of the groups (Figure
4.1, F).
4.3.2 Histology/Histomorphometry
4.3.2.a Synovium
At 4 weeks, a Kruskal Wallis test indicated that there was a significant difference in distribution
of the Total Synovitis scores (TSS) between the three treatment groups (p=0.006). Further pairwise
comparisons using the Dunn-Bonferroni approach indicated that the only significant difference in TSS
was between the DMM+Media (median = 4.25) and the Sham+Media groups (median = 0)(p=0.013).
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At 8 weeks, a Kruskal Wallis test indicated that there was a significant difference in distribution of the
TSS between the three treatment groups (p=0.033). Further pairwise comparisons using the DunnBonferroni approach indicated that the difference between Sham+CHIKV (median = 1.06) and
DMM+PBS (median = 3.75) groups approached significance (p=0.051).

Figure 4.1. Serologic measurements of RANKL, OPG and RANKL:OPG ratio for mice at 4 and 8
weeks post-surgery/3 and 7 weeks post-inoculation. Mean + SEM. Horizontal bars denote significant
differences.
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4.3.2.b Articular Cartilage
At 8 weeks post-surgery, both the DMM+CHIKV and the Sham+CHIKV groups had
significantly lower AC.Ar than the DMM+PBS group (p=0.027 and p=0.001, respectively) (Figure 4.2,
A). Similarly, both the DMM+CHIKV and the Sham+CHIKV groups had significantly lower AC.Th than
the DMM+PBS group (p=0.033 and p=0.002, respectively) (Figure 4.2, B).
4.3.2.c Chondrocyte Cell Death
Some degree of cartilage necrosis was histologically apparent in all treatment groups (Figure
4.3, A, C, and E). Both the DMM+PBS and DMM+CHIKV groups had significantly higher CCD.Ar than
the Sham+CHIKV group (p=0.000 and p=0.001, respectively) (Figure 4.2, C). Similarly, both the
DMM+PBS and DMM+CHIKV groups had significantly higher CCD/AC than the Sham+CHIKV group
(p=0.000 and p=0.001, respectively) (Figure 4.2, D).

Figure 4.2. Histomorphometry results for articular cartilage measurements at 8 weeks post-surgery/7
weeks post-inoculation, including articular cartilage area (AC.Ar) and thickness (AC.Th), chondrocyte
cell death area (CCD.Ar), and proportion of dead chondrocytes (CCD/AC). Mean + SEM. Horizontal
bars denote significant differences.
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4.3.2.d ACS and Safranin O Stains
There were no significant differences in the ACS scores between any of the treatment groups.
There was a significant difference in the distribution of the Safranin O scores in the medial stifle joint
compartment, as indicated by a Kruskal Wallis test (p=0.002). Further pairwise comparisons using the
Dunn-Bonferroni approach indicated that the Safranin O scores for the Sham+CHIKV group (median
= 0) were significantly lower than those for both the DMM+PBS (median = 10) and DMM+CHIKV
(median = 7) groups (p=0.003 and p=0.013, respectively)(Figure 4.3, B, D, and F). There were no
significant differences in the distribution of the Safranin O scores in the lateral stifle joint
compartment.
4.3.2.e Subchondral Bone
The DMM+CHIKV group had a significantly higher SCB.Ar than the Sham+CHIKV group
(p=0.004) (Figure 4.4, A). Similarly, the DMM+CHIKV group had a significantly higher SCB.Th than
the Sham+CHIKV group (p=0.001) (Figure 4.4, B).
4.3.2.f Abaxial Osteophytes
Both the DMM+CHIKV and Sham+CHIKV groups had significantly lower Ab.OP than the
DMM+PBS group (p=0.043 and p=0.000, respectively) (Figure 4.4, C). Also, the Sham+CHIKV group
had a significantly lower Ab.OP than the DMM+CHIKV group (p=0.000).
4.3.3 Microcomputed Tomography (µCT)
4.3.3.a Subchondral Bone
BV was significantly greater in the DMM+PBS group as compared to both the DMM+CHIKV
and the Sham+CHIKV groups at 8 weeks post-surgery (p=0.011 and p=0.000, respectively) (Figure
4.5, A). Additionally, tissue density in the DMM+CHIKV group was significantly greater than the
Sham+CHIKV group (p = 0.001) (Figure 4.5, B).
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Figure 4.3. Stifle joints from mice at 8 weeks post DMM surgery/7 weeks post inoculation. (A, C, and
E) Images demonstrating regions of articular cartilage necrosis bounded by arrowheads (A –
DMM+PBS, C – DMM+CHIKV, E – Sham+CHIKV) (H&E). (B, D, and F) Corresponding Safranin O
stains from the same mice in A, C, and E, exhibiting decreased uptake of stain indicating loss of
proteoglycans (bounded by arrowheads), which correspond with the regions of cartilage necrosis (B –
DMM+PBS, D – DMM+CHIKV, F – Sham+CHIKV) (Safranin O).
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Figure 4.4. Histomorphometry results for subchondral bone and osteophyte measurements at 8
weeks post-surgery/7 weeks post-inoculation, including subchondral bone area (SCB.Ar) and
thickness (SCB.Th), and area of abaxial osteophytes (Ab.OP). Mean + SEM. Horizontal bars denote
significant differences.

Figure 4.5. µCT results for subchondral bone and osteophyte measurements at 4 weeks post
surgery/3 weeks post inoculation and 8 weeks post surgery/7 weeks post inoculation, including total
medial + cranial osteophyte volume (Osteophyte TV), total subchondral bone volume (SCB BV), and
subchondral bone tissue density (SCB Tissue Density). Mean + SEM. Horizontal bars denote
significant differences.
4.3.3.b Medial + Cranial Osteophytes
There were no significant differences in the combined medial and cranial osteophyte TV
between any of the groups at either 4 or 8 weeks (Figure 4.5, C and D). However, subjective
evaluation of the 3D reconstructions of stifle joints at 8 weeks post DMM surgery demonstrated more
extensive proliferation of new bone in the DMM+PBS as compared to the DMM+CHIKV groups
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(Figure 4.6). There was no observable proliferation of osteophytes in the Sham+CHIKV group. There
was also clear medial displacement of the medial meniscus in both the DMM+PBS and DMM+CHIKV
groups demonstrating successful DMM surgeries, while there was no displacement of the medial
meniscus in the Sham+CHIKV group.

Figure 4.6. µCT 3D reconstructions of stifle joints from mice at 8 weeks post-surgery/7 weeks postinoculations. (A and B) DMM+PBS group – demonstrating medial displacement of the medial
meniscus and proliferative osteophytes, most severe on medial and cranial aspects of the femur and
tibia, as well as on the distal aspect of the patella. (C and D) DMM+CHIKV group – demonstrating
medial displacement of the medial meniscus and less prominent proliferative osteophytes on medial
and cranial aspects of the femur and tibia. (E and F) Sham+CHIKV group – demonstrating no medial
displacement of the medial meniscus and no obvious osteophyte proliferation.
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4.4 DISCUSSION
4.4.1 Serology
These experiments demonstrated that at 3 weeks post-inoculation, CHIKV infection alone
resulted in a significant increase in the RANKL:OPG ratio, as a result of an increase in RANKL and
concurrent decrease in OPG. It has been previously reported that CHIKV infection can result in
transient increases in RANKL:OPG ratios of protein levels and mRNA expression within infected
joints in a mouse model of CHIKV infection; however, serological measurements were not
evaluated35. Additionally in that study, Chen et al. demonstrated a return to normal in mRNA
expression by 3 DPI, and it should be noted, that juvenile mice were utilized. As bone modeling
dynamics in immature skeletons are much different than bone remodeling in mature skeletons,
caution should be taken when interpreting those results40,169. However, the current experiments
demonstrated that similar alterations in RANKL and OPG can occur at later timepoints post infection
in an adult animal model, providing additional supporting evidence that CHIKV infection alters RANKL
and OPG and thus, bone remodeling dynamics.
Chen et al. also demonstrated significant increases in serum RANKL and RANKL:OPG ratios
in human serum samples from people infected with CHIKV; results which were mirrored in the mouse
model in the current experiments35. It has also been demonstrated in vitro that CHIKV can infect
human osteoblasts and result in increases in RANKL and decreases in OPG, demonstrating that
alterations in bone dynamics may, at least in part, be a direct result of viral infection of osteoblasts122.
Increases in RANKL:OPG ratio would favor bone resorption over bone protection, consistent with
reports that CHIKV infection may result in erosive lesions of bone103,104.
Interestingly, though results indicated that viral infection alone was associated with an increase
in the RANKL:OPG ratio, there was no significant difference between the DMM+Control groups and
the DMM+CHIKV groups at either 4 or 8 weeks post-surgery. This suggests that pre-existing OA may
suppress or prevent the effects that CHIKV infection has on systemic levels of RANKL and OPG. The
mechanism of this is unclear, however, as the pathophysiology of OA includes significant new bone
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formation in the form of development of osteophytes and subchondral bone sclerosis130, a
RANKL:OPG ratio that favors bone protection or formation may be a component of disease. Thus, in
regard to RANKL:OPG ratios, it seems that the necessity of new bone formation associated with
progression of OA outweighs the potential bone resorptive trend associated with CHIKV infection.
Unfortunately, the published data regarding OA, RANKL and OPG in humans is limited and
sometimes conflicting, in regard to the direction of alteration in the RANKL:OPG ratio166. These
differences are potentially due to variations in bone dynamics throughout the disease course and the
heterogeneity of pathogenesis of OA. Within the DMM surgery groups, though not statistically
significant, the mice concurrently infected with CHIKV did have increased RANKL:OPG ratios as
compared to their control counterparts. It is possible that larger group sizes for future experiments
may help determine if these differences could be significant. Regardless, it seems clear that CHIKV
infection can impact RANKL and OPG levels, demonstrating a potential impact on bone dynamics.
It should be noted that it has been previously suggested that serologic RANKL and OPG
protein measurements may sometimes be unreliable and not reflect local expression88. Therefore
future studies examining mRNA and protein expression within the affected tissues could further
elucidate the impact of CHIKV on alteration of bone dynamics and clarify some of the discrepancies
seen in the current experiments. However, because relatively rapid and inexpensive measurements
of serum RANKL and OPG can be performed in a clinical setting, these may be more practical during
widespread disease outbreaks. As such, since there is a clear difference in the RANKL:OPG ratios
between Sham+CHIKV and DMM+CHIKV animals at the 3-week post infection timepoint, these
measurements could be useful in differentiating between CHIKV infection and CHIKV infection with
concurrent underlying OA during the acute stages of infection. Advanced imaging techniques are the
mainstay for diagnosing OA132, though these may not be available for patient assessment in some
regions affected by CHIKV. The ability to differentiate these disease processes serologically could be
useful in a clinical setting as it may guide treatment decisions.
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4.4.2 Synovitis
There were no significant differences in Total synovitis scores (TSS) between the
DMM+Control groups and the DMM+CHIKV groups at either 4 or 8 weeks post-surgery. However, at
4 weeks there was a significantly higher TSS for the DMM+Media group as compared to the
Sham+Media group; at 8 weeks the difference between the DMM+PBS groups and the Sham+Media
group approached significance. This may suggest that at these stages of disease, OA results in more
significant synovial alterations than CHIKV infection. This is an unexpected finding, because CHIKV is
considered to be an inflammatory arthritis, while OA is degenerative and inflammation is generally
considered to be secondary104,166. Therefore, one might expect that synovitis associated with CHIKV
infection be more severe than that associated with OA. However, it is possible that inflammation is
more severe in earlier stages of OA, as seen in these experiments, whereas the inflammation
associated with CHIKV infection may be subsiding at these same timepoints. Therefore additional
timepoints (both earlier and later) should be examined to determine the relationship between
inflammation and disease progression for both OA and CHIKV.
4.4.3 Articular Cartilage
CHIKV infection alone resulted in chondrocyte cell death in some mice, consistent with our
previously reported results utilizing the footpad injection mouse model, and further demonstrating that
CHIKV infection can cause articular cartilage damage during subacute stages of disease60. However,
OA resulted in more severe chondrocyte necrosis than CHIKV alone, and concurrent CHIKV infection
did not cause any increase in chondrocyte death in animals with pre-existing OA, demonstrating that
infection does not exacerbate this particular disease manifestation.
The results indicating that both the Sham+CHIKV and DMM+CHIKV groups have smaller
articular cartilage area and thickness than those in the DMM+PBS group were the opposite of what
was expected. It has been previously demonstrated that OA results in decreased articular cartilage
thickness and area as it progresses and generally, these decreases are associated with increased
cartilage necrosis114. While the differences in area and thickness were statistically significant, the data
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only represent differences of approximately 0.007 mm2 and 7-10 microns, respectively, and therefore
may be biologically insignificant and simply represent slight differences in plane of section that
happened to coincide with treatment groups.
4.4.4 Osteophytes
Although the µCT analyses did not demonstrate a significant difference in osteophyte volume,
the data showed a higher osteophyte volume in the DMM+PBS group as compared to the
DMM+CHIKV group. Furthermore, histomorphometry data confirmed that CHIKV infection had a
significant impact on osteophyte formation. While CHIKV infection alone does not result in any
osteophyte formation at these timepoints, CHIKV infection in an animal with pre-existing OA resulted
in significantly smaller osteophytes as compared to mice with OA alone. This suggests that CHIKV
infection may have an inhibitory effect on osteophyte bone formation.
When considering these findings in conjunction with the aforementioned alterations in the
RANKL:OPG ratio, these results indicate that CHIKV alters RANKL and OPG levels to create an
environment which favors bone resorption over bone protection or formation, which ultimately may
impact and subsequently decrease the formation of osteophytes at later timepoints. Though this
alteration in the RANKL:OPG ratio does not completely prevent the new bone osteophyte formation, it
may result in a slight alteration in the balance in the formation-resorption axis, thus slowing the
progression of osteophyte formation. Though the serological levels of RANKL and OPG were not
significantly different between the DMM+Control and the DMM+CHIKV groups, the RANKL:OPG ratio
in the latter was higher than that in the former. Additionally, it is possible that local expression is
affected, though not systemically observable. As previously discussed, future studies comparing local
mRNA and protein expression may resolve this discrepancy.
4.4.5 Subchondral Bone
The significantly increased subchondral bone area and thickness in the DMM+CHIKV mice
compared to the Sham+CHIKV mice indicates that the OA surgery results in an increase in
subchondral bone associated with progression of OA. These results are consistent with the current
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literature regarding OA pathogenesis, which states that OA results in subchondral bone sclerosis49,89.
Interestingly, the results from the µCT analyses were slightly different in that the DMM+PBS group
had a significantly higher subchondral bone BV than both the DMM+CHIKV and Sham+CHIKV
groups. Though the BV of the DMM+CHIKV and Sham+CHIKV did not differ significantly, the
DMM+CHIKV group was higher than the Sham+CHIKV group. These data may suggest that while OA
results in expected increases in subchondral bone, concurrent infection with CHIKV diminishes the
amount of new subchondral bone formed. This suppressive effect on new bone formation is similar to
that described above concerning osteophyte bone formation. In regard to measurements of
subchondral bone, the µCT results may be considered more accurate than the histomorphometry, as
µCT measures 3D total subchondral bone volume, whereas the histomorphometry evaluation
measures thickness and area from a single 2D image16 and only evaluated the medial compartment
of the joint.
4.4.6 Clinical Significance
Interestingly, when considering the results of decreased osteophyte formation and subchondral
bone sclerosis associated with CHIKV infection in a mouse with pre-existing OA, one might be
tempted to conclude that CHIKV infection actually slows the progression of OA rather than
exacerbating disease as hypothesized. However, care should be taken when drawing this conclusion.
While increases in osteophyte volumes and subchondral bone volume are standard parameters for
measuring OA severity, they are not the only factors to consider74. In regard to OA pathophysiology,
though there is still much controversy regarding underlying mechanisms of disease, cartilage damage
and loss is often considered a primary lesion, and subchondral bone sclerosis and osteophyte
formation secondary developments which represent the adaptive response of bone to combat the
pathologic changes in cartilage loss and joint instability resulting from alterations in load within the
joint49,58. The articular cartilage and subchondral bone are intimately interconnected from a functional
and physiological perspective, and alterations in either can impact the structure and function of the
other95. In fact, it has been demonstrated that histomorphometric alterations in subchondral bone
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directly correlate with cartilage lesion severity12. Some studies have also suggested that osteophytes
are important in maintaining joint stability in cases of osteoarthritis58. Therefore, CHIKV infection may
be suppressing the adaptive response of bone to cartilage loss and joint instability by diminishing new
bone formation.
Of additional consideration, alterations in subchondral bone and osteophytes do not
necessarily correlate with clinically appreciable pain associated with OA. In fact, many studies have
found that MRI results such as synovitis, effusion, and cartilage volume/thickness often better
correlate with clinical pain74,96,101. Studies have also shown that radiological severity of OA, which
includes evaluation of subchondral bone changes and osteophytes, often poorly correlate with
clinically appreciable pain, particularly in OA involving the knee joint101. Some reports have also
stated that there is inadequate long-term pain outcomes in patients that underwent knee replacement
surgeries, though this procedure should ensure that the structural changes such as osteophyte
formation and subchondral bone sclerosis are “cured”74.
Furthermore, in the current experiments, CHIKV infection had no impact on the progression or
severity of cartilage necrosis in cases of pre-existing OA. Additionally, the synovitis scores for OA and
OA+CHIKV were similar, indicating that CHIKV infection does not alter this aspect of OA disease at
the timepoints examined. As previously stated, presence and severity of synovitis correlates well with
clinical assessments of pain74. Therefore, at the stage of disease examined in this project, the
presence of OA may be more painful than CHIKV alone and higher levels of pain felt by some
patients in acute stages of infection may warrant more thorough clinical evaluation including
advanced imaging, so that other concurrent arthritic diseases can be ruled out.
When considering all of these findings together, one could conclude that while CHIKV infection
does not exacerbate cartilage necrosis and synovitis associated with OA at these timepoints, it does
suppress the natural responses of bone aimed at counteracting the effects of these primary lesions.
Therefore, one could view the impacts of CHIKV on OA progression as detrimental, because they
prevent these responses, and uncouple the cartilage/subchondral bone/osteophyte relationship that
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occurs with OA progression. It is unclear at this point what long-term impact these alterations may or
may not have on OA progression or clinical presentation. It has been determined that cartilage and
subchondral bone changes can have feedback effects on each other, such that as cartilage
degenerates, subchondral bone sclerosis occurs, altering the redistribution and absorption of forces,
resulting in additional cartilage degeneration186. It is currently unclear if the diminished subchondral
bone formation associated with concurrent CHIKV infection may impact the progression of cartilage
necrosis.
Additionally, in a clinical setting, care should be taken when evaluating patients with concurrent
OA and CHIKV-associated joint disease, because the current data demonstrate that CHIKV has a
suppressive effect on the secondary changes associated with OA, which are often used to
radiologically determine disease severity20. In other words, when evaluating patients with both
diseases concurrently, standard methods of determining OA disease severity, such as evaluation of
osteophytes and subchondral bone, may underestimate the severity of underlying cartilage damage
and synovial changes. Of additional importance from a clinical perspective, because CHIKV and OA
have opposite effects on bone dynamics (i.e. resorption vs. formation, respectively), care should be
taken when utilizing any treatment options that may impact bone dynamics (such as bisphosphonates
or RANKL antagonists) in cases of concurrent disease.
In conclusion, CHIKV infection has a significant impact on the progression of pre-existing OA,
though not in the way that was hypothesized. CHIKV infection does not result in exacerbation of
cartilage necrosis or synovitis associated with the pre-existing disease at the timepoints examined in
these experiments. However, in regard to disease manifestations of OA associated with new bone
formation, CHIKV has a suppressive effect, which may be associated with alterations in the systemic
levels of RANKL and OPG. The long-term implications for these alterations in regard to the continued
progression of OA are unclear. Further experiments focusing on later timepoints would help elucidate
the effects of these concurrent disease processes. Additionally, examination of local protein and
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mRNA expression of RANKL and OPG within affected joints could help further elucidate the impacts
of CHIKV infection on bone remodeling dynamics.
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CHAPTER 5: SUMMARY AND DISCUSSION
Chikungunya virus (CHIKV) is widespread throughout the tropics and subtropics and
subsequently has the potential to affect more than 1 billion people, representing a significant threat to
human health and well-being182. Infection results in disease in 95% of people, and manifestations
consist of high fever, rash and a severe, debilitating polyarthralgia6,181. Because current therapies are
only supportive, infected people often suffer throughout the acute stage of disease, and as a result,
many remain bedridden for 1-3 weeks during the acute stages, resulting in absence from work and
lost wages162. This results in a significant reduction in quality of life and, in conjunction with the
medical expenses associated with diagnostics, therapeutics, and hospitalization, represents a
substantial economic impact, on top of the direct health effects134,162,174. It has also been reported that
in a variable proportion of patients, chronic arthralgia/arthritis may develop in the months to years
following resolution of acute symptoms141. The mechanisms of this aspect of disease are currently
unknown. The research presented in this dissertation focused on elucidating the pathogenesis of
bone and joint disease associated with CHIKV infection. The results of this work have advanced the
understanding of disease processes and have demonstrated previously un- or under-recognized
manifestations.
By using three different mouse models, we have demonstrated in chapters 2, 3, and 4 that
CHIKV infection can cause irreversible and progressive cartilage damage. While cartilage necrosis is
assumed to occur in human cases of CHIKV-induced arthritis and has recently been demonstrated in
an immunodeficient mouse model129, the extent of these manifestations and their progression had not
been previously confirmed or reported. These findings are significant because cartilage necrosis is
often considered irreversible75, demonstrating that early intervention during acute CHIKV disease
when these lesions occur is crucial. Also, the progression of these cartilage lesions in subacute or
chronic stages of disease, in conjunction with persistent CHIKV antigen within the synovium and
other tissues, suggests a mechanism by which at least some of the reported chronic cases of CHIKVinduced joint disease may occur.
85

In addition, the presence of significant periostitis and periosteal bone proliferation during the
21-30 DPI time periods of disease identifies a novel mechanism for the severe pain manifestations
experienced in humans. The periosteum is a highly innervated structure and thus any pathologic
disturbances have the potential to result in severe pain7. In fact, periostitis and periosteal bone
proliferation, which can occur in other diseases such as hypertrophic pulmonary osteoarthropathy,
are considered extremely painful and traditional anti-inflammatory and pain management
medications, such as NSAIDs, have variable success rates121. This may, in part, explain why there is
also a variable success rate of NSAID use for pain relief in acute stages of CHIKV disease.
Therefore, this finding may suggest that alternative strategies for pain management that focus on
alleviation of this manifestation, such as bisphosphonates, may be of benefit121.
Furthermore, while correlations have been made between pre-existing joint diseases such as
osteoarthritis (OA) and more severe CHIKV joint disease, no studies have attempted to examine the
interactions between these two diseases. Our research has demonstrated that CHIKV infection and
subsequent disease can have a significant impact on manifestations associated with pre-existing OA
(Chapter 4). As OA affects 22.7% (52.5 million) of adults in the United States alone, the likelihood that
any infected individuals may have subclinical or clinical OA prior to infection is high28. Therefore, an
understanding of the impact that CHIKV-induced disease may have on pre-existing OA is essential.
The results reported here demonstrate that CHIKV infection results in significant reductions in
new bone formation (subchondral bone and osteophytes) that is usually associated with progression
of OA. As this new bone formation is often considered a compensatory response to primary cartilage
damage and joint instability49,58, this impact can be considered a detrimental effect on pre-existing
disease. Of additional note, cartilage damage cannot be easily assessed in patients with joint
disease, therefore progression of these secondary bony changes are often used as indicators of
overall disease progression and severity20. Because CHIKV has a suppressive effect on these
aspects of disease, the ability to monitor disease progression using these manifestations may be
impaired. In other words, progression of alterations in subchondral bone and osteophyte proliferation
86

may underestimate cartilage damage and changes in joint stability in patients that have concurrent
OA and CHIKV-associated joint disease.
Of additional importance, we have demonstrated in Chapters 2 and 3 that CHIKV infection
results in alterations in the serological parameters RANKL and OPG in two of our mouse models.
Furthermore, these alterations are associated with some of the aforementioned changes in bone,
such as resolution/reversal of the periosteal bone proliferation seen in the C57BL/6 footpad model,
and potentially also with changes in subchondral bone and osteophytes in the OA/CHIKV model. With
additional research, the significance of these alterations and their exact correlations with disease
manifestations can be elucidated and their potential utility in a clinical setting as disease-monitoring
tools can be determined. It is possible that these measurements could be used as surrogates for
disease manifestations in bone to assess and track these alterations, so that continued evaluation via
advanced imaging might not be necessary.
It should be noted that the use of multiple mouse models in these studies has both positive
and negative connotations. Demonstration of some of the similar manifestations in multiple models
adds credence to the conclusions that these are important manifestations of CHIKV induced disease,
particularly with respect to cartilage damage. However, there are some challenges and drawbacks to
each of the models utilized. With respect to the IRF 3/7 -/- -/- mice, because CHIKV results in severe,
fatal disease within 7 days of infection, this model cannot be used for subacute or chronic studies.
Additionally, because this type of severe disease is rare in humans73, the significance and relevance
of some of the manifestations demonstrated, such as widespread vasculitis and ischemic bone
marrow necrosis, are unknown. Because full autopsies on fatal cases of CHIKV are rarely performed
and/or reported, it is unclear if similar manifestations occur in people in those cases73.
When considering the C57BL/6 footpad injection mouse model, there are many positives and
negatives. Because this model develops more protracted disease similar to that seen in people, and
no alterations to the innate or adaptive immune responses have been made in these mice,
manifestations in these mice may be more closely mirror those in humans. This model also allows
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introduction of the virus via a more natural route, as compared to the intra-articular model (to be
discussed below). Furthermore, this model could be easily altered to deliver virus via mosquito,
resulting in a completely natural route of infection. Additionally, because adult mice were utilized, as
compared to juveniles utilized in other CHIKV studies, the alterations on bone dynamics and joint
manifestations as they relate to adult patients with CHIKV disease are likely more accurate. We have
also demonstrated progressive cartilage damage, ongoing synovitis, and persistence of viral antigen
associated with CHIKV infection in this model, thus demonstrating its potential use in more detailed
studies of chronic CHIKV disease.
The biggest drawback to this model lies in the anatomical location of the virus inoculation and
the subsequent joints that are examined. Because joint manifestations at sites distant to the injection
are inconsistent, only joints of the inoculated foot can be evaluated in detail. These joints are quite
challenging to evaluate via histology and obtaining adequate and comparable tissue samples
between individuals is extremely challenging. This makes assessment of local changes in the joints,
in addition to potential alterations of cytokine expression in the synovium (when assessed by in situ
hybridization) difficult, if not impossible. Additionally, these small joints have very thin layers of
articular cartilage, and are not as similar to human joints as some of the larger mouse joints, such as
the stifle. One must also consider that some degree of joint disease was demonstrated in chronic
stages, even in the control mice within this cohort, likely as a result of naturally occurring OA.
Because these are difficult joints to evaluate and progression of OA has not been extensively studied
in this location, interpretation of these findings as they relate to CHIKV infection can be challenging.
The C57BL/6 intra-articular injection model solves some of these problems. The stifle joint is
considered much more similar to human joints, and extensive evaluation of these joints has been
performed in numerous studies110,114,169. Additionally, it is easier to process these tissues for
histologic evaluation and ensure that consistent samples are obtained for comparisons. The biggest
downside to this model is the somewhat “unnatural” route of inoculation. In order to ensure that viral
arthritis occurs in the stifle, the virus has to be directly injected into the joint space, which would not
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occur in natural infections. However, intra-articular injection of infectious agents for evaluation of joint
manifestations has been utilized for other diseases, particularly in regard to septic arthritis5,21,81,106,165,
and thus should be considered a viable model. Unfortunately, because virus is not injected into the
surrounding tissues, some of the manifestations, such as periostitis and periosteal bone proliferation
may not occur, as these may require virus outside of the joint space and/or inflammation in the
adjacent tissues. As long as these potential drawbacks are recognized prior to experimentation, all of
the mouse models utilized in these studies can contribute to the current knowledge regarding CHIKVinduced disease.
To build upon the results presented here and continue to add to the body of CHIKV
pathogenesis research, additional experiments can be performed to further elucidate specific
mechanisms of disease and their manifestations. Because we have determined that the adult
C57BL/6 mouse model demonstrates chronic cartilage damage and synovitis associated with
persistence of viral antigen, this model can be utilized for further experiments examining chronic
CHIKV-induced disease. While in previous experiments, RT-PCR has demonstrated virus in joint
associated tissues of mice and primates 16 weeks and 90 days post-infection, respectively,
localization of antigen within the joints themselves was not demonstrated65,93. The results presented
herein clearly indicate that viral antigen remains within the subintima of the synovium demonstrating a
mechanism for ongoing synovitis and joint pain.
In future experiments, the footpad and intra-articular models can be used to further evaluate
local expression of cytokines, including RANKL, OPG, and others that are associated with acute
inflammation and ongoing joint damage (e.g. IL-1β, IL-6, TNF-alpha, MMPs). This will help determine
exact mechanisms of ongoing joint damage and potential avenues for therapeutic intervention. In vitro
experiments have shown that CHIKV can infect osteoblasts and result in alterations in RANKL and
OPG production122. Therefore, these mouse models could be used to determine if similar
mechanisms occur in vivo. Alternatively, or perhaps concurrently, CHIKV could alter RANKL
production and osteoclastogenesis via infection of synoviocytes, as has also been demonstrated in
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vitro127. Because of the quality of the tissue sections utilized for IHC in the current experiments, it
could not be definitively determined if viral antigen is present within bone, cartilage or periosteum,
specifically. By utilizing the intra-articular injection model, with which more consistent and higher
quality samples can be procured, these specific tissues can be evaluated for persistence of viral
antigen.
While we have shown that CHIKV infection can have a negative impact on pre-existing joint
disease such as OA, the long-term effects on disease progression are still unknown. Examination of
later timepoints, such as 16 weeks post-surgery, will help further establish the impacts of initial
CHIKV infection on OA progression. It is currently unclear how alteration of the compensatory
changes in subchondral bone and osteophyte proliferation may affect the overall progression of OA,
including ongoing cartilage damage and synovitis.
The current research has demonstrated novel mechanisms of bone and joint disease including
potential new sources of pain, which may have consequences for intervention and treatment
strategies in cases of CHIKV infection. It has also demonstrated potential mechanisms of continued
joint damage, including lending additional support to the hypothesis that persistence of viral antigen
plays a role in chronic disease. These are also the first experiments to demonstrate a negative impact
of CHIKV infection and subsequent joint disease on pre-existing OA, which could have tremendous
importance in disease management regarding the current ongoing and potentially expanding
outbreak in the western hemisphere.
While the results presented in this dissertation add to our understanding of CHIKV-associated
joint disease, as discussed in Chapter 1, challenges still exist in determining all of the pathogenic
mechanisms involved in CHIIKV-associated arthritis, particularly in regard to the use of animal
models and chronic disease. To date, no animal models have demonstrated the lesions and
progression of chronic disease that has been reported in people167. However, it is still unclear
whether this is due to inadequacy of the animal models or to the ambiguities surrounding chronic
CHIKV-associated arthritis. Although there have been numerous cases of chronic CHIKV-associated
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joint disease reported in the literature, none have actually determined a causal relationship with viral
infection79,163. Rather, these diagnoses were made based on a presence of chronic joint disease and
CHIKV infection at some point in the past. None of these reports adequately eliminated pre-existing
joint disease at the time of initial infection, and in many cases, did not rule out other causes of chronic
joint disease13,15,160. In fact, some reports have determined that people diagnosed with chronic
CHIKV-associated joint disease meet the requirements to be diagnosed with rheumatoid arthritis,
spondyloarthropathy, or other immune-mediated joint disease79.
While some researchers have stated that this suggests CHIKV infection may result in
development of these immune-mediated disease, or that viral persistence is to blame23,24,65,105, it is
highly possible that many of these people could have developed these conditions in the absence of
CHIKV infection, or had unrecognized subclinical disease at the time of infection. Thus, what are
currently defined as cases of chronic CHIKV-associated arthritis likely represent a heterogeneous
group of disorders with varying pathogeneses. When one considers that even a fairly well studied
condition such as rheumatoid arthritis is still poorly understood, it becomes clear how difficult
determining the potential pathogenesis of chronic CHIKV arthritis is.
Therefore, as we move forward, it is necessary to perform prospective studies in human cases,
in which pre-exiting joint disease is ruled out at the initial time of infection via advanced imaging
techniques such as MRI, followed by monitoring for development of chronic disease. Additionally,
more thorough clinical evaluations during both acute and chronic stages of disease, including
synovial fluid analyses and evaluation of synovial biopsies, would help establish any potential
relationships between viral infection and development of chronic joint disease. This, coupled with
continued use of the animal models described herein will ultimately be necessary to determine the
pathogenesis of both acute and chronic disease associated with CHIKV infection.
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